Upload
doanthien
View
223
Download
0
Embed Size (px)
Citation preview
Supplementary Online Content
Pearse RM, Harrison DA, MacDonald N, et al; OPTIMISE Study Group. Effect of a perioperative, cardiac output–guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: a randomized clinical trial and updated systematic review. JAMA. doi:10.1001/jama.2014.5305
eAppendix 1. Standard Operating Procedure: Management of Intervention Group Patients
eAppendix 2. Additional Systematic Review Methods, Results, and Reference List
eTable 1. Nonadherence With Peri-operative, Cardiac Output-Guided, Hemodynamic Therapy Algorithm
eTable 2. Additional Staff Present From Investigating Team During Intervention Period (During Surgery and Six Hours Following Surgery)
eTable 3. Pre-specified Sub-group Analyses for Primary Outcome
eFigure 1. Flow Diagram Describing Selection of Studies for Systematic Review and Meta-analysis
eFigure 2. Forest Plot of Meta-analysis for Patients Developing Infection
eFigure 3. Forest Plot of Meta-analysis for Length of Hospital Stay
eFigure 4. Forest Plot of Meta-analysis for Mortality at Either 28 Days or 30 Days or Hospital Mortality, According to Definition Used by the Authors of Each Paper
eFigure 5. Forest Plot of Meta-analysis for Mortality at Longest Follow-up
Study Protocol
This supplementary material has been provided by the authors to give readers additional information about their work.
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
Doc Ref: SOP 009 Version 3.0
Page 1 of 4 Effective Date: 08/02/2012
eAppendix 1. Standard Operating Procedure (SOP)
Management of intervention group patientsSOP 009
Scope
To provide guidance on management of patients who have been allocated the interventiongroup in the Optimise Trial.
The procedures for administering the intervention are described in detail below and a summaryis provided on page 4.
Procedure
The trial intervention period will commence at the start of general anaesthesia and continue forsix hours after surgery is complete (maximum total duration: 24 hours).
Cardiac output monitoring
Immediately following induction of anaesthesia, the LiDCOrapid system will be set up formonitoring of cardiac output.
General haemodynamic measures
Care for all patients has been loosely defined to avoid extremes of clinical practice but also for practice misalignment, as follows: Patients will receive 5% dextrose at 1 ml/kg/hr as maintenance fluid. An alternative
maintenance fluid may be administered (using the same rate of 1ml/kg/hr) at the discretion ofthe treating clinician. Additional fluid will be administered at the discretion of the clinician,guided by the pulse rate, arterial pressure, urine output, core-peripheral temperature gradient,serum lactate and base deficit/excess.
Blood will be transfused to maintain haemoglobin at greater than 8 g/dl. Oxygenation will be maintained at Sp02 94% or greater. Heart rate will be maintained at less than 100 beats per minute. Core temperature will be maintained at 37°C.
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
Doc Ref: SOP 009 Version 3.0
Page 2 of 4 Effective Date: 08/02/2012
Mean arterial pressure will be maintained between 60 and 100 mmHg using an alphaadrenoceptor agonist or vasodilator as required, although other measures such as adjustmentsto anaesthesia and analgesia should be considered first.
Post-operative analgesia and sedation
Post-operative analgesia will be provided by epidural infusion (bupivicaine and fentanyl) orintravenous infusion (morphine or fentanyl).
If required, post-operative sedation will be provided with propofol or midazolam.
Plasma potassium and glucose monitoring
Monitoring of plasma potassium and glucose levels is recommended.
Administering fluid to a stroke volume end-point
Currently, peri-operative intra-venous fluid is usually administered to subjective end-points. Theuse of stroke volume as a treatment end-point may significantly reduce but not eliminate thissubjectivity. However, the measurement of stroke volume does not replace the discretion of thetreating clinician in ensuring patient safety. The protocol allows for the treating clinician toadjust both the volume and type of fluid administered, e.g. if there is concern about persistenthypovolaemia or fluid overload. Such decisions may relate to clinical circumstances orphysiological measurements (e.g. pulse rate, arterial pressure, urine output, serum lactate,base excess).
Stroke volume will be determined by arterial waveform analysis (LiDCOrapid system). In orderto ensure a standardised approach to fluid administration, no more than 500ml of intra-venousfluid will be administered prior to commencing cardiac output monitoring.
Patients will receive 250ml fluid challenges, within duration of five minutes, with a colloidsolution as required, aiming to maximise stroke volume. Maximal stroke volume is defined asthe absence of a sustained rise in stroke volume of at least 10% sustained for 20 minutes ormore in response to a fluid challenge.
Once the maximal value of stroke volume is determined, this should be maintained throughoutthe intervention period with colloid boluses as required. Initial increases in stroke volume areoften only transient. If stroke volume does not increase as defined above, it is likely that theheart is functioning on the horizontal part of the Starling curve (see figure). This suggests thepatient is not hypovolaemic and fluid challenges should be stopped. If the stroke volumedecreases, this is most likely due to ongoing fluid losses and a further fluid challenge isrequired.
Many peri-operative physiological changes may alter the maximal value of stroke volume.These may be due to general and regional anaesthesia, surgical stimulation, endotracheal tube
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
Doc Ref: SOP 009 Version 3.0
Page 3 of 4 Effective Date: 08/02/2012
removal, pain, fluid loss, etc. Further fluid challenges should be considered where there is reason to believe the maximal stroke volume may have changed. The most challenging situation is the patient who clearly remains stroke volume responsive despite large volumes of intra-venous fluid. This arises when an evolving severe fluid deficit has yet to become clinically apparent in any other respect. Experience from previous trials suggests that it is particularly important to continue to give fluid challenges in such patients to maintain maximal stroke volume. The small volume of each individual fluid challenge will minimise any potential adverse effects of confirming volume status in euvolaemic patients. Data from previous studies confirm the safety of this approach.
Dopexamine:
Patients in the intervention group will also receive dopexamine at a fixed rate of 0.5 g/kg/min,to be commenced after the first fluid challenge and continued throughout the interventionperiod. Because of the vasodilator effects of dopexamine, correction of hypovolaemia (ifpresent) should be initiated at least 30 minutes prior to commencement of the infusion. Thedose of dopexamine should be reduced to 0.25 g/kg/min if the heart rate increases to greaterthan 120% of the baseline value or to more than 100bpm (whichever is the greater) for morethan 30 minutes despite adequate volume replacement, anaesthesia and analgesia. If, despitedose reduction, the heart rate does not decrease below this level, the dopexamine infusionshould be discontinued.
What if blood products or intravenous fluids are required for indications unrelated to changes in stroke volume?
Many patients will require blood products and, in some cases, additional intravenous fluidchallenges may be requested by a clinician. Administration of colloid, blood or blood productsunder these circumstances should be guided by stroke volume monitoring and these datashould be used to inform the need for subsequent fluid challenges.
0 4 8 12 160
2
4
6
8
Right atrial pressure(mmHg)
Car
dia
c o
utp
ut
/ V
eno
us
retu
rn
(lm
in-1
)
Figure: Starling’s curve The increase in venous return due to intra-venous fluid (red arrows) increases stroke volume in responsive patients. At maximal stroke volume (horizontal part of curve), the absence of a response indicates fluid is not required.
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
Doc Ref: SOP 009 Version 3.0
Page 4 of 4 Effective Date: 08/02/2012
General haemodynamic measures
1. 5% dextrose at 1 ml/kg/hr or an alternative maintenance fluid may be
administered (using the same rate of 1ml/kg/hr) at the discretion of the treating
clinician
2. Transfuse blood to maintain haemoglobin >8 g/dl
3. Clinician retains discretion to adjust therapy if concerned about risks of
hypovolaemia or fluid overload
4. Mean arterial pressure 60-100 mmHg; Sp02 ≥94%; core temperature 37°C;
Administering fluid to a stroke volume end-point
1. 250ml colloid boluses to achieve a maximal value of stroke volume[
2. No more than 500ml fluid to be given before cardiac output monitor is attached
3. Fluid challenges should not be continued in patients who are not fluid
responsive in terms of a stroke volume increase
4. Fluid responsiveness is defined as a stroke volume increase ≥10%
5. If stroke volume decreases further fluid challenge(s) are indicated
6. Persistent stroke volume responsiveness suggests continued fluid loss
Dopexamine
1. Start dopexamine infusion at fixed rate of 0.5 g/kg/min after first colloid fluid
challenge
2. Halve dose if heart rate rises to the greater of: (a) >120% of baseline value, or
(b) >100bpm for more than 30 minutes.
3. Stop dopexamine if tachycardia persists
Summary
What if blood or IV fluid is required regardless of stroke volume?
1. If blood products or additional fluid challenges are required, then stroke volume
should still be monitored to identify any change in maximal stroke volume
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
eAppendix 2. Additional Systematic Review Methods, Results, and Reference List
Extended methods Using identical methods, we updated the previous Cochrane systematic review of published randomized trials of ‘Peri-operative increase in global blood flow to explicit defined goals and outcomes following surgery’ with the findings of the OPTIMISE Trial and other published trials identified by an updated search. Full text of the review is available online (http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004082.pub5/pdf). CENTRAL (Cochrane Library 2014), MEDLINE (1966 to February 2014) and EMBASE (1982 to February 2014) were searched for randomized trials involving adult patients (≥16 years) undergoing surgery in an operating room where the intervention met the following criteria: Peri-operative administration of fluids, with or without inotropes/vasoactive drugs, targeted to increase blood flow (relative to control) against explicit measured goals. We included RCTs, with or without blinding, that were available as full published papers. We applied no language restrictions. We included adults (aged 16 years or older) undergoing surgery in an operating theatre. The intervention was defined as peri-operative administration (initiated within 24 hours before surgery and lasting up to 6 hours after surgery) of fluids, with or without inotropes/vasoactive drugs, to increase blood flow (relative to control) against explicit measured goals defined as: cardiac output, cardiac index, oxygen delivery, oxygen delivery index, oxygen consumption, stroke volume, stroke volume index, mixed venous oxygen saturation, oxygen extraction ratio or lactate. The detailed search strategies are presented below.
Two independent investigators identified titles and abstracts of potentially eligible studies. We resolved any disagreement by discussion. We obtained the full texts of potentially eligible studies. We abstracted the study characteristics including: study design; patient population; interventions; and outcomes. Two investigators independently extracted data. We achieved consensus by resolving any disparity in data collection by discussion. In the absence of appropriate published data, we made at least one attempt to contact authors of eligible studies to obtain any required data. The analysis was performed with the best available information when there was no response. We selected the following key outcomes: number of patients with complications (primary outcome variable for the OPTIMISE trial), number of infections, length of postoperative hospital stay, mortality at longest follow-up (primary outcome variable of Cochrane systematic review) and 28 day or 30 day or hospital mortality (as reported by authors of component trials). Many studies reported complications as total numbers of complications, rather than patients with complications, and we do not report these outcomes due to unit of analyses issues. We applied the intention-to-treat method for all analyses. Treatment effects were reported as relative risks (RR) with 95% CI for clinical variables or weighted mean differences (SD) for length of hospital stay. Empty cells, occurring as a result of studies in which no events were observed in one or both arms, were corrected for by the addition of a fixed value (0.5) to all cells with an initial value of zero. The chi-squared test was used to assess whether observed differences in results are compatible with chance alone. A large chi-squared statistic (I2 statistic) provides evidence of heterogeneity of intervention effects (variation in effect estimates beyond chance). I2 values less than 30% suggest a low likelihood of such statistical heterogeneity. Analyses were performed using Review Manager (RevMan 5.2.8) using fixed effects models for the primary outcome variable and random effects models in sensitivity analyses. Fixed effects models were chosen for the primary analysis in the original Cochrane review due to the low level of statistical heterogeneity for this outcome in this group of studies (I2 = 12%) and because this approach tends to provide a more conservative estimate in the presence of small studies effects (which are present in this review). The results of random effects are provided in the eAppendix for comparison. The report has been prepared in accordance with the PRISMA guidelines (www.prisma-statement.org).
Search strategy for CENTRAL, The Cochrane Library #1 (Vasoactive or Fluid* or Drug Administration or fluid therapy or starch or gelatin* or crystalloid* or colloid* or splanchnic* or pulmonary artery flotation or catheter* or PAFC or Swan Ganz or Doppler):ti,ab #2 ((fluid* near (load* or administrat*)) or (perfusion near (renal or tissue))) #3 base near (acid or excess or deficit) #4 Venous near (Oxygen Saturation) #5 ((Stroke Volume Index) or (Oxygen Consumption Index)):ti,ab #6 (oxygen near (delivery or consumption or saturation)):ti,ab #7 (cardiac near (output or index)):ti,ab #8 (lactat* or CVP or pHi or PCO2 or SvO2 or VO2 or DO2 or Tonometry):ti,ab #9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8) #10 ((surg* or operat*) near (general or high?risk or vascular or cardiac or cancer or trauma* or emergency or orthopaed*)):ti,ab
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
#11 (peri?operativ* or post?operativ* or intra?operativ* or optimi?ation or goal?directed or supra?normal or aneurysm):ti,ab #12 (#10 OR #11) #13 (#9 AND #12)
Search strategy for MEDLINE (OvidSP) 1. Fluid-Therapy/ or Body-Fluids/ or Catheterization-Swan-Ganz/ or Catheterization/ or Heart-Catheterization/2. (Vasoactive or Fluid* or Drug Administration or fluid therapy or starch or gelatin* or crystalloid* or colloid*or splanchnic* or pulmonary artery flotation or catheter* or PAFC or Swan Ganz or Doppler).ti,ab. 3. ((fluid* adj3 (load* or administrat*)) or (perfusion adj3 (renal or tissue))).mp.4.Blood-Volume/ orOxygen-Consumption/ orCentral-Venous-Pressure/ or Stroke-Volume/ orCardiac-Output/or Echocardiography/ or Echocardiography-Doppler/ 5. ((base adj3 (acid or excess or deficit)) or ((Venous adj3 Oxygen Saturation) or Stroke Volume Index orOxygen Consumption Index)).mp. or ((oxygen adj3 (delivery or consumption or saturation)) or (cardiac adj3 (output or index)) or lactat* or CVP or pHi or PCO2 or SvO2 or VO2 or DO2 or Tonometry).ti,ab. 6. 1 or 2 or 3 or 4 or 57. Perioperative-Care/ or Intraoperative-Period/ or Postoperative-Period/ or Aneurysm/ or Vascular-Surgical-Procedures/ or Thoracic-Surgery/ or Emergency-Treatment/ or Specialties-Surgical/ or Orthopedics/ or Surgical-Procedures-Operative/ 8. ((surg* or operat*) adj3 (general or high?risk or vascular or cardiac or cancer or trauma* or emergency ororthopaed*)).ti,ab. 9. (peri?operativ* or post?operativ* or intra?operativ* or optimi?ation or goal?directed or supra?normal oraneurysm).ti,ab. 10. 8 or 7 or 911. 6 and 1012. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trialsas topic.sh. or randomly.ab. or trial.ti.) not (animals not (humans and animals)).sh. 13. 11 and 12
Search strategy for EMBASE (OvidSP) 1. fluid therapy/ or body fluid/ or Swan Ganz catheter/ or heart catheterization/ or blood volume/ or oxygenconsumption/ or central venous pressure/ or heart stroke volume/ or heart output/ or Doppler echocardiography/ or echocardiography/ 2. (Vasoactive or Fluid* or Drug Administration or fluid therapy or starch or gelatin* or crystalloid* or colloid*or splanchnic* or pulmonary artery flotation or catheter* or PAFC or Swan Ganz or Doppler).ti,ab. or ((fluid* adj3 (load* or administrat*)) or (perfusion adj3 (renal or tissue))).mp. 3. ((base adj3 (acid or excess or deficit)) or ((Venous adj3 Oxygen Saturation) or Stroke Volume Index orOxygen Consumption Index)).mp. or ((oxygen adj3 (delivery or consumption or saturation)) or (cardiac adj3 (output or index)) or lactate* or CVP or pHi or PCO2 or SvO2 or VO2 or DO2 or Tonometry).ti,ab. 4. 1 or 2 or 35. perioperative period/ or postoperative period/ or aneurysm/ or vascular surgery/ or thorax surgery/ oremergency treatment/ or orthopedics/ or surgery/ 6. ((surg* or operat*) adj3 (general or high?risk or vascular or cardiac or cancer or trauma* or emergency ororthopaed*)).ti,ab. 7. (peri?operativ* or post?operativ* or intra?operativ* or optimi?ation or goal?directed or supra?normal oraneurysm).ti,ab. 8. 6 or 7 or 59. 8 and 410. (placebo.sh. or controlled study.ab. or random*.ti,ab. or trial*.ti,ab.) not (animals not (humans andanimals)).sh. 11. 10 and 9
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
Results The updated literature search identified eight additional trials including OPTIMISE, to provide a total of 38 trials that included 6595 participants with 23 trials including 3024 participants providing data describing our primary outcome (eFigure 1). For the fixed effects models, the addition of the findings of OPTIMISE and other recent trials does not substantially alter the findings of the recent Cochrane meta-analysis. Complications were less frequent amongst patients treated according to a hemodynamic therapy algorithm (Intervention 488/1548 [31.5%] vs Controls 614/1476 [41.6%]; RR 0·77 [0·71-0·83]) (Figure 3). The intervention was associated with a reduced incidence of post-operative infection (Intervention 182/836 patients [21·8%] vs Controls 201/790 patients [25.4%]; RR 0·81 [0·69-0.95]) and a reduced duration of hospital stay (mean reduction 0.80 days [0·97-0.62]) (eFigures 2 and 3). There was no significant reduction in hospital / 28 day / 30 day mortality (Intervention 159/3215 deaths [4.9%] vs Controls 206/3160 deaths [6·5%]; RR 0·82 [0·67-1·01]) and a non-significant reduction in mortality at longest follow-up (Intervention 267/3215 deaths [8.3%] vs Controls 327/3160 deaths [10.3%]; RR 0·86 [0·74-1·00]) (eFigures 4 and 5).
The use of random effects models did not substantially alter the findings for the incidence of complications (RR 0.73 [0.65-0.82]), or post-operative infection (0.81 [0.69-0.95]). The reduction in duration of hospital stay increased slightly (mean reduction days 1.15 days [1.82-0.48]), and the reduction in both hospital / 28 day / 30 day mortality (0.82 [0.67-1.01]), and mortality at longest follow-up (0.73 [0.58-0.92]) were strengthened.
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
Manuscripts identified in updated literature search and included in systematic review
*denotes new trial since original systematic review
1. Bender JS, Smith-Meek MA, Jones CE. Routine pulmonary artery catheterization does not reducemorbidity and mortality of elective vascular surgery: results of a prospective, randomized trial. Annals ofSurgery. 1997; 226(3): 229–36.
2. Berlauk JF, Abrams JH, Gilmour IJ, O’Connor SR, Knighton DR, Cerra FB. Preoperative optimization ofcardiovascular haemodynamics improves outcome in peripheral vascular surgery. A prospective,randomized clinical trial. Ann Surg. 1991; 214(3): 289–97.
3. Bonazzi M, Gentile F, Biasi GM, Migliavacca S, Esposti D, Cipolla M, et al.Impact of perioperativehaemodynamic monitoring on cardiac morbidity after major vascular surgery in low risk patients. Arandomised pilot trial. Eur Jour Vasc Endovasc Surg. 2002; 23(5): 445–51.
4. Boyd O, Grounds RM, Bennett ED. A randomized clinical trial of the effect of deliberate perioperativeincrease of oxygen delivery on mortality in high-risk surgical patients. JAMA 1993; 270: 2699–707.
5. *Brandstrup B, Svendsen P, Rasmussen M, Belhage B, Rodt S, Hansen B, Møller D, Lundbech L, Andersen N, Berg V, Thomassen N, Andersen S, Simonsen L. Which goal for fluid therapy during colorectal surgery is followed by the best outcome: near-maximal stroke volume or zero fluid balance? Br Joour Anaesth. 2012; 109: 191-9.
6. Cecconi M, Fasano N, Langiano N, Divella M, Costa MG, Rhodes A, et al.Goal-directed haemodynamictherapy during elective total hip arthroplasty under regional anaesthesia. Crit Care 2011;15:R132.
7. Challand C, Struthers R, Sneyd JR, Erasmus PD, Mellor N, Hosie KB, et al.Randomized controlled trial ofintraoperative goal-directed fluid therapy in aerobically fit and unfit patients having major colorectalsurgery. Brit Jour Anaesth. 2012;108(1):53–62.
8. Conway DH, Mayall, R, Abdul-LatifMS, GilliganS, Tackaberry C. Randomised controlled trialinvestigating the influence of intravenous fluid titration using oesophageal Doppler monitoring duringbowel surgery. Anaesthesia 2002;57(9):845–9.
9. Donati A, Loggi S, Preiser JC, Orsetti G, Munch C, Gabbanelli V, et al.Goal-directed intraoperative therapyreduces morbidity and length of hospital stay in high-risk surgical patients. Chest 2007;132(6):1817–24.
10. Gan TJ, Soppitt A, Maroof M, el Moalem H, Robertson KM, Moretti E, et al.Goal-directed intraoperativefluid administration reduces length of hospital stay after major surgery. Anesthesiology 2002;97(4):820–6.
11. *Goepfert M, Richter H, Zu Eulenburg C, Gruetzmacher J, Rafflenbeul E, Roeher K, von Sandersleben A, Diedrichs S, Reichenspurner H, Goetz A, Reuter D. Individually Optimized Hemodynamic Therapy Reduces Complications and Length of Stay in the Intensive Care Unit: A Prospective, Randomized Controlled Trial. Anesthesiology. 2013; 119: 824-36.
12. Jerez Gomez Coronado V, Robles Marcos M, Perez Civantos D, Tejada Ruiz J, Jimeno Torres B, BarraganGomez Coronado I. Hemodynamic optimization and morbimortality after heart surgery. MedicinaIntensiva. 2001; 25(8): 297–302.
13. Jhanji S, Vivian-Smith A, Lucena-Amaro S, Watson D, Hinds CJ, Pearse RM. Haemodynamic optimisationimproves tissue microvascular flow and oxygenation after major surgery: a randomised controlled trial. CritCare. 2010; 14: R151.
14. Kapoor PM, Kakani M, Chowdhury U, Choudhury M, Lakshmy R, Kiran U. Early goal-directed therapy inmoderate to high- risk cardiac surgery patients. Ann Cardiac Anaesth. 2008; 11(1): 27–34.
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
15. Lobo SM, Salgado PF, Castillo VG, Borim AA, Polachini CA, Palchetti JC, et al. Effects of maximizingoxygen delivery on morbidity and mortality in high-risk surgical patients. Crit Care Med. 2000; 28: 3396-404.
16. Mayer J, Boldt J, Mengistu AM, Rohm KD, Suttner S. Goal-directed intraoperative therapy based on autocalibrated arterial pressure waveform analysis reduces hospital stay in high-risk surgical patients: arandomized, controlled trial. Crit Care. 2010; 14: R18.
17. McKendry M, McGloin H, Saberi D, Caudwell L, Brady AR, Singer M. Randomised controlled trialassessing the impact of a nurse delivered, flow monitored protocol for optimisation of circulatory statusafter cardiac surgery. BMJ 2004; 329(7460): 258–61.
18. Mythen MG, Webb AR. Perioperative plasma volume expansion reduces the incidence of gut mucosalhypoperfusion during cardiac surgery. Arch Surg. 1995; 130:423–9.
19. Noblett SE, Snowden CP, Shenton BK, Horgan AF. Randomized clinical trial assessing the effect ofDoppler optimized fluid management on outcome after elective colorectal resection. Brit Jour Surg. 2006;93(9): 1069-76.
20. Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Early goal-directed therapy aftermajor surgery reduces complications and duration of hospital stay. A randomised, controlled trial[ISRCTN38797445]. Crit Care. 2005; 9(6): R687–93.
21. *Pearse RM, Harrison DA, MacDonald N, Gillies MA, Blunt M, Ackland G, Grocott MP, Ahern A, Griggs K, Scott R, Hinds CJ, Rowan K, for the OPTIMISE study group. Effect of a peri-operative, cardiac output-guided, hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: A multi-center randomized controlled trial. JAMA. 2014
22. Pillai P, McEleavy, Gaughan M, Snowden C, Nesbitt I, Durkan G, et al.A double-blind randomizedcontrolled trial to assess the effect of doppler optimized intraoperative fluid management on outcomefollowing radical cystectomy. Jour Urol. 2011; 186: 2201–6.
23. Pölönen P, Ruokonen E, Hippeläinen M, Pöyhönen M, Takala J. A prospective, randomized study of goaloriented haemodynamic therapy in cardiac surgical patients. Anesth Analg. 2000; 90: 1052–9.
24. *Salzwedel C, Puig J, Carstens A, Bein B, Molnar Z, Kiss K, Hussain A, Belda J, Kirov M, Sakka S, Reuter D. Perioperative goal-directed hemodynamic therapy based on radial arterial pulse pressure variation and continuous cardiac index trending reduces postoperative complications after major abdominal surgery: a multi-center, prospective, randomized study. Critical Care. 2013; 17: R191.
25. Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, et al.A randomized, controlled trial of theuse of pulmonary-artery catheters in high-risk surgical patients. The New England Journal of Medicine2003;348(1):5–14.
26. Senagore AJ, Emery T, Luchtefeld M, Kim D, Dujovny N, Hoedema R. Fluid management for laparoscopiccolectomy: A prospective, randomized assessment of goal-directed administration of balanced salt solutionor hetastarch coupled with enhanced recovery program. Dis Colon Rectum. 2009; 52: 1935-40.
27. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS. Prospective trial of supranormal values ofsurvivors as therapeutic goals in high-risk surgical patients. Chest. 1988; 94:1176–86.
28. Sinclair S, James S, Singer M. Intraoperative intravascular volume optimisation and length of hospital stayafter repair of proximal femoral fracture: randomised controlled trial. BMJ. 1997; 315: 909-12.
29. *Smetkin AA, Kirov MY, Kuzkov VV, et al. Single transpulmonary thermodilution and continuous monitoring of central venous oxygen saturation during off-pump coronary surgery. Acta Anaesthesiol Scand 2009; 53: 505-14.
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
30. Ueno S, Tanabe G, Yamada H, Kusano C, Yoshidome S, Nuruki K, et al. Response of patients withcirrhosis who have undergone partial hepatectomy to treatment aimed at achieving supranormal oxygendelivery and consumption. Surgery. 1998; 123: 278–86.
31. Valentine RJ, DukeML, Inman MH, Grayburn PA,Hagino RT, Kakish HB, et al. Effectiveness ofpulmonary artery catheters in aortic surgery: a randomized trial. Jour Vasc Surg. 1998; 27: 203–11.
32. Van der Linden PJ, Dierick A, Wilmin S, Bellens B, De Hert SG. A randomised controlled trial comparingan intraoperative goal-directed strategy with routine clinical practice in patients undergoing peripheralarterial surgery. Eur Jour Anaesthesiol. 2010; 27: 788-93.
33. Venn R, Steele A, Richardson P, Poloniecki J, Grounds M, Newman P. Randomized controlled trial toinvestigate influence of the fluid challenge on duration of hospital stay and perioperative morbidity inpatients with hip fractures. Brit Jour Anaesth. 2002; 88(1): 65-71.
34. Wakeling HG, McFall MR, Jenkins CS, Woods WG, Miles WF, Barclay GR, et al. Intraoperativeoesophageal Doppler guided fluid management shortens postoperative hospital stay after major bowelsurgery. Brit Jour Anaesth. 2005; 95(5): 634–42.
35. Wilson J, Woods I, Fawcett J, Whall R, Dibb W, Morris C, et al.Reducing the risk of major electivesurgery: randomised controlled trial of preoperative optimisation of oxygen delivery. BMJ. 1999; 318:1099–103.
36. Ziegler DW, Wright JG, Choban PS, Flancbaum L. A prospective randomized trial of preoperative“optimization” of cardiac function in patients undergoing elective peripheral vascular surgery. Surgery.1997; 122: 584–92.
37. *Zhang J, Chen C, Lei X, Feng Z, Zhu S. Goal-directed fluid optimization based on stroke volume variation and cardiac index during one-lung ventilation in patients undergoing thoracoscopy lobectomy operations: a pilot study. Clinics. 2013; 68: 1065-70.
38. *Zheng H, Guo H, Ye J, Chen L, Ma H. Goal-Directed Fluid Therapy in Gastrointestinal Surgery in Older Coronary Heart Disease Patients: Randomized Trial. World J Surg. 2013; 37: 2820-2829.
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
eTab
le 1
. Non
adhe
renc
e w
ith p
eri-o
pera
tive,
car
diac
out
put-g
uide
d, h
emod
ynam
ic
ther
apy
algo
rithm
Al
l dat
a pr
esen
ted
as n
(%).
Doe
s no
t inc
lude
one
usu
al c
are
patie
nt ra
ndom
ized
in e
rror
and
four
pat
ient
s (th
ree
usua
l car
e pa
tient
s an
d on
e he
mod
ynam
ic th
erap
y) w
ho d
id n
ot u
nder
go s
urge
ry.
Car
diac
out
put-
guid
ed
hem
odyn
amic
th
erap
y al
gorit
hm
(n=3
67)
Usu
al c
are
(n=3
62)
Failu
re to
adm
inis
ter d
opex
amin
e to
a h
emod
ynam
ic
ther
apy
algo
rithm
pat
ient
7
(1.9
) N
/A
Adm
inis
tratio
n of
inco
rrec
t dos
e of
dop
exam
ine
to
hem
odyn
amic
ther
apy
algo
rithm
pat
ient
: 26
(7.1
) N
/A
Low
est r
ate
of d
opex
amin
e le
ss th
an 0
.5 µ
g/kg
/min
8
(2.2
) N
/A
Hig
hest
rate
of d
opex
amin
e gr
eate
r tha
n 0.
5 µg
/kg/
min
1
(0.3
) N
/A
Dop
exam
ine
adm
inis
tere
d fo
r les
s th
an s
ix h
ours
fo
llow
ing
surg
ery
20
(5.4
) N
/A
Failu
re to
mon
itor c
ardi
ac o
utpu
t in
hem
odyn
amic
ther
apy
algo
rithm
pat
ient
3
(0.8
) N
/A
Adm
inis
tratio
n of
dop
exam
ine
to u
sual
car
e pa
tient
N
/A
1 (0
.3)
Use
of c
ardi
ac o
utpu
t mon
itorin
g in
usu
al c
are
patie
nt
N/A
31
(8.6
)
Ove
rall
com
plia
nce
(non
e of
abo
ve m
et)
334
(91.
0)
330
(91.
2)
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
eTab
le 2
. A
dditi
onal
sta
ff pr
esen
t fr
om i
nves
tigat
ing
team
dur
ing
inte
rven
tion
perio
d (d
urin
g su
rger
y an
d si
x ho
urs
follo
win
g su
rger
y). A
ll da
ta p
rese
nted
as
n (%
). D
oes
not i
nclu
de o
ne u
sual
car
e pa
tient
rand
omiz
ed in
erro
r an
d fo
ur p
atie
nts
(thre
e us
ual
care
pat
ient
s an
d on
e he
mod
ynam
ic t
hera
py)
who
did
not
und
ergo
sur
gery
. One
pat
ient
(he
mod
ynam
ic
ther
apy
algo
rithm
) mis
sing
dat
a on
add
ition
al s
taff.
Car
diac
out
put-g
uide
d he
mod
ynam
ic th
erap
y al
gorit
hm
(n=3
66)
Usu
al c
are
(n=3
62)
Dur
ing
surg
ery
Six
hour
s fo
llow
ing
surg
ery
Dur
ing
surg
ery
Six
hour
s fo
llow
ing
surg
ery
Add
ition
al s
taff
pres
ent:
Add
ition
al n
urse
21
2 (5
7·9)
22
8 (6
2·3)
79
(21·
8)
33 (9
·1)
Add
ition
al d
octo
r 77
(21·
0)
83 (2
2·7)
83
(22·
9)
7 (1
·9)
Add
ition
al n
urse
and
doc
tor
60 (1
6·4)
33
(9·0
) 7
(1·9
) 0
(0)
Rol
e of
add
ition
al s
taff:
O
bser
vatio
n 6
(1·6
) 7
(1·9
) 98
(27·
1)
5 (1
·4)
Dat
a co
llect
ion
10 (2
·7)
9 (2
·5)
20 (5
·5)
22 (6
·1)
Adv
isin
g on
inte
rven
tion
94 (2
5·7)
54
(14·
8)
36 (9
·9)
8 (2
·2)
Del
iver
ing
inte
rven
tion
239
(65·
3)
274
(74·
9)
15 (4
·1)
5 (1
·4)
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
eTab
le 3. P
re-s
peci
fied
sub-
grou
p an
alys
es fo
r prim
ary
outc
ome
Dat
a pr
esen
ted
as n
(%).
*Exc
lude
s ei
ght p
atie
nts
(two
hem
odyn
amic
ther
apy
algo
rithm
, six
usu
al c
are)
from
two
site
s w
hich
recr
uite
d fe
wer
than
10
patie
nts.
Doe
s no
t inc
lude
one
usu
al c
are
patie
nt ra
ndom
ized
in e
rror
and
thre
e pa
tient
s (o
ne u
sual
car
e pa
tient
and
two
hem
odyn
amic
ther
apy)
who
w
ithdr
ew c
onse
nt.
Car
diac
out
put-
guid
ed,
hem
odyn
amic
th
erap
y al
gorit
hm
Usu
al c
are
Adj
uste
d od
ds ra
tio
(95%
CI)
Test
for
inte
ract
ion
p-va
lue
Urg
ency
of s
urge
ry
0.53
E
lect
ive
127
(35.
9)
(n=3
54)
152
(43.
3)
(n=3
51)
0.72
(0
.52-
0.99
)
Emer
genc
y 7
(58.
3)
(n=1
2)
6 (4
6.2)
(n
=13)
1.
24
(0.2
3-6.
74)
Plan
ned
surg
ical
pro
cedu
re c
ateg
ory
0.70
Upp
er g
astro
inte
stin
al
39 (3
6.1)
(n
=108
) 47
(41.
2)
(n=1
14)
0.83
(0
.47-
1.47
)
Low
er g
astro
inte
stin
al
56 (3
3.5)
(n
=167
) 62
(38.
0)
(n=1
63)
0.82
(0
.51-
1.31
)
Sm
all b
owel
+/-
panc
reas
37
(43.
0)
(n=8
6)
47 (5
6.6)
(n
=83)
0.
53
(0.2
8-0.
99)
Uro
logi
cal o
r gyn
aeco
logi
cal
surg
ery
invo
lvin
g gu
t 2
(40.
0)
(n=5
) 2
(50.
0)
(n=4
) 0.
62
(0.0
4-10
.20)
Tim
ing
of re
crui
tmen
t*
0.01
9 Ea
rlier
(fi
rst 1
0 pa
tient
s pe
r site
) 33
(42.
3)
(n=7
8)
28 (3
4.1)
(n
=82)
1.
51
(0.7
5-3.
01)
Late
r (a
ll su
bseq
uent
pat
ient
s)
100
(35.
0)
(n=2
86)
129
(46.
7)
(n=2
76)
0.59
(0
.41-
0.84
)
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
eFigure 1. Flow diagram describing selection of studies for systematic review and meta-analysis
Records identified through database searching
(n=19,022)
Additional records identified through other sources
(n=5)
Records after duplicates removed (n=10,537)
Records screened (n=10,537)
Records excluded (n=10,396)
Full-text articles assessed for eligibility
(n=80)
Full-text articles excluded (n=42)
Not surgical patients (n=19) Not flow goals or goals same in both groups (n=15) Not RCT (n=3) Other (n=5) Studies included in
qualitative synthesis (n=38)
Studies included in meta-analysis
(n=38)
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
eFig
ure
2. F
ores
t plo
t of m
eta-
anal
ysis
for p
atie
nts
deve
lopi
ng in
fect
ion.
*N
ew tr
ials
iden
tifie
d in
upd
ated
lite
ratu
re s
earc
h. S
ize
of d
ata
mar
kers
cor
resp
onds
to w
eigh
ting
for e
ach
com
pone
nt tr
ial.
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
eFig
ure
3. F
ores
t plo
t of m
eta-
anal
ysis
for l
engt
h of
hos
pita
l sta
y.
*New
tria
ls id
entif
ied
in u
pdat
ed li
tera
ture
sea
rch.
Siz
e of
dat
a m
arke
rs c
orre
spon
ds to
wei
ghtin
g fo
r eac
h co
mpo
nent
tria
l.
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
eFig
ure
4. F
ores
t plo
t of m
eta-
anal
ysis
for m
orta
lity
at e
ither
28
days
or 3
0 da
ys o
r hos
pita
l mor
talit
y,
acco
rdin
g to
def
initi
on u
sed
by th
e au
thor
s of
eac
h pa
per
*New
tria
ls id
entif
ied
in u
pdat
ed li
tera
ture
sea
rch.
Siz
e of
dat
a m
arke
rs c
orre
spon
ds to
wei
ghtin
g fo
r eac
h co
mpo
nent
tria
l.
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
eFig
ure
5. F
ores
t plo
t of m
eta-
anal
ysis
for m
orta
lity
at lo
nges
t fol
low
-up
*New
tria
ls id
entif
ied
in u
pdat
ed li
tera
ture
sea
rch.
Siz
e of
dat
a m
arke
rs c
orre
spon
ds to
wei
ghtin
g fo
r eac
h co
mpo
nent
tria
l.
© 2014 American Medical Association. All rights reserved.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 1 1st December 2011
Optimisation of Peri-operativeCardiovascular Management to
Improve Surgical Outcome
Trial Protocol Version 4.0
1st December 2011
REC reference: 09/H0703/23 EudraCT No: 2009-009596-35
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 2 1st December 2011
Trial description
Open, multi-centre, randomised controlled trial of stroke volume guided fluid therapy and low
dose dopexamine infusion compared to usual care in patients undergoing major abdominal
surgery involving the gastrointestinal tract.
Chief Investigator
Rupert Pearse MBBS BSc FRCA MD DipICM
Senior Lecturer in Intensive Care Medicine
Barts and The London School of Medicine & Dentistry
Intensive Care Unit
Royal London Hospital
London
E1 1BB
United Kingdom
Tel: 0207 377 7299
Fax: 0207 377 7299
1st December 2011
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 3 1st December 2011
Funding source National Institute of Health Research (NIHR) and Intensive Care National Audit & Research Centre (ICNARC)
SponsorBarts and The London School of Medicine & Dentistry, Queen Mary’s University of London.
Mr Gerry Leonard
Joint Research & Development Office
Queen Mary University of London
Lower Ground Floor
The QMI Building
5 Walden Street
Whitechapel
London
E1 2EF
Tel: 020 7882 7260
Fax: 020 7882 7276
Trial Management Intensive Care National Audit & Research Centre Clinical Trials Unit (ICNARC CTU)
Tavistock House
Tavistock Square
London
WC1H 9HR
Tel: 020 7554 9784
Fax: 020 7388 3759
Trial Manager: Miss Aoife Ahern, ICNARC
Trial Statistician: Dr David Harrison, ICNARC
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 4 1st December 2011
Table of Contents
TRIAL SUMMARY........................................................................................................................7
ABSTRACT ..................................................................................................................................9
SCHEDULE OF ABBREVIATIONS ...........................................................................................10
BACKGROUND..........................................................................................................................12
OBJECTIVE................................................................................................................................14
TRIAL DESIGN...........................................................................................................................14
PRIMARY OUTCOME MEASURE.......................................................................................................14
SECONDARY OUTCOME MEASURES ...............................................................................................14
INCLUSION CRITERIA ....................................................................................................................15
EXCLUSION CRITERIA....................................................................................................................15
RECRUITMENT AND SCREENING.....................................................................................................16
INFORMED CONSENT.....................................................................................................................16
RANDOMISATION ..........................................................................................................................17
TRIAL INTERVENTIONS ...........................................................................................................17
PERI-OPERATIVE MANAGEMENT FOR ALL PATIENTS .......................................................................17
ADDITIONAL PERI-OPERATIVE MANAGEMENT FOR THE INTERVENTION GROUP .................................18
ADDITIONAL PERI-OPERATIVE MANAGEMENT FOR THE CONTROL GROUP.........................................18
PROCEDURES TO MINIMISE BIAS....................................................................................................19
DATA SET COLLECTION..........................................................................................................19
TRIAL DRUG..............................................................................................................................22
SOURCING, MANUFACTURE AND SUPPLY OF IMP ...........................................................................22
PACKAGING, RECEIPT, STORAGE, DISPENSING AND RETURN OF IMP ..............................................22
PRESCRIPTION AND LABELLING OF IMP.........................................................................................23
ADMINISTRATION OF IMP..............................................................................................................24
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 5 1st December 2011
GENERAL PRECAUTIONS FOR USE OF DOPEXAMINE WITHIN THE OPTIMISE TRIAL.............................24
IMP DATA COLLECTION IN THE CASE RECORD FORM.....................................................................25
PRIOR AND CONCOMITANT THERAPIES...........................................................................................25
SUBJECT COMPLIANCE MONITORING .............................................................................................25
PREDEFINED PROTOCOL DEVIATIONS AND VIOLATIONS ..................................................................26
WITHDRAWAL OF PARTICIPANTS ...................................................................................................26
PRIMARY SAFETY ENDPOINTS........................................................................................................26
SAMPLE SIZE CALCULATION..........................................................................................................26
STATISTICAL ANALYSIS.................................................................................................................27
PLANNED SUB-GROUP ANALYSES .................................................................................................27
INTERIM ANALYSIS ........................................................................................................................27
SAFETY AND ADVERSE EVENTS ...........................................................................................28
ADVERSE EVENT (AE) ..................................................................................................................28
ADVERSE REACTION (AR) ............................................................................................................28
SERIOUS ADVERSE EVENT (SAE) .................................................................................................28
SUSPECTED SERIOUS ADVERSE REACTION (SSAR)......................................................................29
SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTION (SUSAR)..............................................29
EXPECTED ADVERSE AND SERIOUS ADVERSE EVENTS....................................................................29
RECORDING AND DOCUMENTING OF ADVERSE EVENTS (AES)........................................................30
PHARMACOVIGILANCE REPORTING (SAE AND SUSAR).................................................................31
ECONOMIC ANALYSIS .............................................................................................................32
SUB-STUDIES............................................................................................................................33
BIOLOGICAL SUB-STUDY...............................................................................................................33
MARKERS OF PRE-LOAD RESPONSIVENESS SUB-STUDY .................................................................34
END OF TRIAL AND STOPPING RULES .................................................................................35
DATA STORAGE .......................................................................................................................35
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 6 1st December 2011
CONFIDENTIALITY....................................................................................................................35
TRIAL MONITORING, AUDIT AND INSPECTION ....................................................................36
MONITORING SAFETY AND WELL BEING OF TRIAL PARTICIPANTS................................37
MONITORING SAFETY OF INVESTIGATORS .........................................................................38
ETHICAL CONSIDERATIONS...................................................................................................38
TRIAL SPONSORSHIP AND INDEMNITY ................................................................................38
FUNDING....................................................................................................................................40
PUBLICATION ...........................................................................................................................40
REFERENCES ...........................................................................................................................42
AAPPENDIX 1: DEFINITION OF POST-OPERATIVE COMPLICATIONS................................45
APPENDIX 2: CLASSIFICATION OF URGENCY OF SURGERY.............................................53
APPENDIX 3: RISK FACTORS FOR CARDIAC OR RESPIRATORY DISEASE .....................54
APPENDIX 4: POST-OPERATIVE MORBIDITY SURVEY (POMS)..........................................55
APPENDIX 5: EQ5D QUESTIONNAIRE (EUROQOL) ..............................................................58
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 7 1st December 2011
Trial Summary
Title Optimisation of Peri-operative Cardiovascular Management to Improve Surgical Outcome
Short title Optimise
Protocol version Version 4.0, 1st December 2011
Methodology Open, multi-centre, randomised controlled trial
Trial duration 2 years
Trial Sites 17
Primary objective To establish whether the use of minimally invasive cardiac output monitoring to guide protocolised administration of intra-venous fluid, combined with low dose dopexamine infusion will reduce the number of patients who experience complications within 30 days following major surgery involving the gastro-intestinal tract.
Number of patients 734
Inclusioncriteria
Adult patients undergoing major abdominal surgery involving the gastrointestinal tract that is expected to take longer than 90 minutes will be eligible for recruitment provided they satisfy one of the following criteria:
Age 65 years and over
Or…
Age 50-64 plus, one or more of:
- non-elective surgery;
- acute or chronic renal impairment (serum creatinine >130 �mol/l);
- diabetes mellitus;
- presence of a risk factor for cardiac or respiratory disease.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 8 1st December 2011
Statisticalmethodology
Primary analyses will be unadjusted by Fisher’s exact test for binary outcomes and t-tests, or non-parametric alternatives, for continuous outcomes. Logistic and linear regression will be used to perform analyses adjusted for baseline data. Outcomes will be analysed on an intention to treat basis. Significance will be set at p<0.05.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 9 1st December 2011
Abstract
Complications following major surgery are an important cause of death and disability.
A high-risk population of surgical patients accounts for over 80% of deaths but only
12.5% of in-patient surgical procedures. There are approximately 170,000 high-risk
surgical procedures each year in the UK. Around 12% of this population die and as
many as 70% develop complications.
A number of small single centre studies suggest that the use of cardiac output
monitoring to guide the administration of intra-venous fluids and inotropes may
improve outcome for patients undergoing high-risk surgery. However, this approach
to peri-operative care has yet to be incorporated into routine practice. The most
notable reason for this is the doubt surrounding the wider applicability of the findings
of previous clinical trials.
The aim of this multi-centre trial is to evaluate the effects of the use of cardiac output
monitoring to guide peri-operative haemodynamic therapy on the number of patients
who develop complications following major abdominal surgery in high-risk patients. In
addition, economic analysis will be performed to provide the data necessary for
widespread implementation of this treatment approach should our hypothesis prove
correct.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 10 1st December 2011
Schedule of abbreviations
AE Adverse Event
AR Adverse Reaction
ASA American Society of Anesthesiologists
CI Chief Investigator
CRF Case Report Form
DMEC Data Monitoring and Ethics Committee
GCP Good Clinical Practice
GDHT Goal Directed Haemodynamic Therapy
GMP Good Manufacturing Practice
HR Hazard Ratio
ICNARC Intensive Care National Audit & Research Centre
IMP Investigational Medicinal Product
MAOI Monoamine Oxidase Inhibitors
MHRA Medical and Healthcare products Regulatory Agency
MET Metabolic Equivalent
NCEPOD National Confidential Enquiry into Peri-Operative Death
OR Odds Ratio
PI Principal Investigator
POMS Post-Operative Morbidity Survey
POSSUM Physiologic and Operative Severity Score for the
enUmeration of Mortality and Morbidity
QALY Quality Adjusted Life Years
SAE Serious Adverse Event
SAR Serious Adverse Reaction
SOP Standard Operating Procedure
SUSAR Serious Unexpected Suspected Adverse Reaction
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 11 1st December 2011
SmPC Summary of Product Characteristics
SSAR Suspected Serious Adverse Reaction
SSI Surgical Site Infection
TMG Trial Management Group
TSC Trial Steering Committee
WMD Weighted Mean Difference
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 12 1st December 2011
Background
Complications following major surgery are an important cause of death and disability.
High-risk surgical patients account for over 80% of post-operative deaths but only
12.5% of in-patient procedures.1, 2 Over 170,000 high-risk surgical procedures are
performed each year in the UK, following which more than 100,000 patients will
develop complications resulting in over 25,000 deaths.1-4 Patients who develop
complications but survive, remain on hospital wards for many days until well enough
to be discharged.1-4 In the long term, such patients suffer a reduction in functional
independence and a substantially decreased life expectancy.5 There is an urgent
need to develop interventions which will improve outcome for high-risk surgical
patients, regardless of the availability of critical care resources.
The findings of a number of studies indicate that derangements in cardiac output,
global oxygen delivery and related variables are strongly associated with post-
operative complications and death.6-11 These observations led to the suggestion that
cardiac output and oxygen delivery could be used as haemodynamic end-points to
which the doses of intra-venous fluid and inotropic therapy could be carefully titrated
during the peri-operative period. This approach, sometimes termed Goal Directed
Haemodynamic Therapy (GDHT), is believed to improve outcome by augmenting
oxygen delivery to the tissues. Although GDHT has been evaluated in many clinical
trials, the evidence base for this approach is problematic and inconclusive. The
findings of trials have proved inconsistent because of important methodological
variations including differences in patient group, timing and duration of interventions,
treatment end-points, therapies used to achieve end-points and choice of monitoring
technology. In surgical patients, some trials identified reductions in morbidity12-19 and
mortality.20-22 Others, however failed to show any benefit,23-28 particularly in the case
of vascular surgery.24-27 Concern has been expressed that harmful effects, in
particular myocardial ischaemia, may result from the high doses of inotropic therapy
administered to some patients who receive GDHT. Most importantly, there have been
no large multi-centre clinical trials to evaluate the effect of haemodynamic therapy,
guided by cardiac output, on outcomes after surgery.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 13 1st December 2011
In recent investigations, GDHT protocols have been refined to address key issues of
safety and practicality, whilst remaining as effective as those used in earlier trials.16, 17
These indicate an approach to peri-operative GDHT which maximises patient benefit
and safety whilst minimising the requirement for additional resources, in particular the
need to routinely admit patients to a critical care unit. If effective, this intervention
could therefore be rapidly introduced into all NHS hospitals after a short period of
training. Retrospective economic analyses suggest the minimal capital investment
and running costs would be more than offset by reductions in duration of hospital
stay.29, 30
A meta-analysis of four studies of oesophageal Doppler guided intra-operative fluid
therapy in patients undergoing major abdominal surgery identified a significant
reduction in post-operative complications (OR 0.32 [0.19–0.52]; p<0.0001) and
duration of hospital stay (WMD 1.68 days [2.39–0.98]; p<0.0001) for patients
receiving Doppler guided fluid therapy, although there was no significant reduction in
mortality (OR 0.32 [0.03–3.14]; p=0.33).31 A further meta-analysis of cardiac output
monitoring guided intra-operative fluid therapy in patients undergoing major
abdominal surgery identified very similar reductions in post-operative complications
(OR 0.28 [0.17-0.46]; p<0.0001) and duration of hospital stay (WMD 1.60 days [0.62-
2.58]; p=0.001) but again no reduction in mortality (OR 0.62 [0.16-2.45]; p=0.50).32
The findings of a meta-regression analysis of clinical trials of peri-operative
dopexamine infusion (agent most commonly used to increase global oxygen delivery
in this setting) suggest that low dose dopexamine (�1 μg/kg/min) is associated with a
50% reduction in 28 day mortality when compared to control treatment (low dose
dopexamine 6.3% vs. control 12.3%; OR 0.50 [0.28-0.88]; p=0.016).33 Duration of
post-operative stay was also significantly reduced in the low dose dopexamine group
(median 13 vs. 15 days; HR 0.75 [0.64–0.88]; p=0.0005) but was unaffected in the
high dose dopexamine group. These meta-analyses highlight the uncertainty
surrounding the possible benefits of peri-operative GDHT and the need for a large
multi-centre clinical trial to resolve this. The aim of this large multi-centre trial is to
evaluate the effects of peri-operative haemodynamic therapy guided by cardiac
output on the number of patients who develop complications following major gastro-
intestinal surgery.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 14 1st December 2011
Objective
To establish whether the use of minimally invasive cardiac output monitoring to guide
protocolised administration of intra-venous fluid, combined with low dose
dopexamine infusion will reduce the number of patients who experience
complications within 30 days following major surgery involving the gastro-intestinal
tract.
Trial Design
An open, multi-centre, randomised controlled trial.
Primary outcome measure
� Difference in the number of patients developing post-operative complications
or dying within 30 days following randomisation between treatment arms (see:
Appendix 1 for definitions of post-operative complications).
Secondary outcome measures
� Difference in 30-day post-operative mortality between treatment arms
� Difference in morbidity identified with the Post-Operative Morbidity Survey
(POMS) for patients still in hospital on day 7 following randomisation
� Difference in the number of patients developing infectious complications
within 30 days following randomisation
� Difference in duration of post-operative hospital stay
� Difference in 30-day critical care free days (i.e. alive and not in critical care)
� Difference in 180-day post-operative mortality
� Difference in cost-effectiveness
� Difference in healthcare costs
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 15 1st December 2011
Inclusion Criteria
Adult patients undergoing major abdominal surgery involving the gastrointestinal tract that is expected to take longer than 90 minutes will be eligible for recruitment provided they satisfy one of the following criteria: Age 65 years and over
Or…
Age 50-64 plus, one or more of:
� non-elective surgery (see Appendix 2);
� acute or chronic renal impairment (serum creatinine >130 �mol/l);
� diabetes mellitus;
� presence of a risk factor for cardiac or respiratory disease (see Appendix 3).
Exclusion criteria
The exclusion criteria are:
� refusal of consent;
� patients receiving palliative treatment only (likely to die within 30 days);
� acute myocardial ischaemia (within 30 days prior to randomisation);
� acute pulmonary oedema (within 7 days prior to randomisation);
� septic shock;
� thrombocytopenia (platelet count <50 x 109/l);
� patients receiving Monoamine Oxidase Inhibitors (MAOIs);
� phaeochromocytoma;
� severe left ventricular outlet obstruction e.g. due to hypertrophic obstructive
cardiomyopathy or aortic stenosis;
� known hypersensitivity to dopexamine hydrochloride or disodium edetate;
� participating in another randomised trial;
� pregnancy at time of enrolment;
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 16 1st December 2011
� failure to meet the inclusion criteria.
Recruitment and screening
Potential participants will be screened by research staff at Site having been identified
from pre-admission clinic lists, operating theatre lists and by communication with the
relevant nursing and medical staff.
Informed consent
It is the responsibility of the Principal Investigator (PI) at each site, or persons
delegated by the PI to obtain written informed consent from each subject prior to
participation in this trial. This process will include provision of a patient information
sheet accompanied by the relevant consent form, and an explanation of the aims,
methods, anticipated benefits and potential hazards of the trial. Wherever possible,
the patient will be approached at least 24 hours prior to surgery to allow time for any
questions. However, by the nature of the inclusion criteria for this trial, many patients
will undergo emergency surgery or arrive in hospital on the morning of surgery.
Provided that all reasonable effort has been made to identify a potential participant
24 hours in advance of surgery, they will still be eligible for recruitment within a
shorter time frame if this has not proved possible. The most frequent reason will be
that the patient is undergoing surgery on an urgent or emergency basis.
The PI or designee will explain to all potential participants that they are free to refuse
to enter the trial or to withdraw at any time during the trial, for any reason. If new
safety information results in significant changes in the risk/benefit assessment, the
patient information sheet and consent form will be reviewed and updated if
necessary. However, given the short duration of the intervention period, it is most
unlikely that new safety information would come to light for an individual patient.
Patients who lack capacity to give or withhold informed consent will not be recruited.
Patients who are not entered into this trial should be recorded (including reason not
entered) on the patient screening log in the Optimise Investigator Site File.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 17 1st December 2011
Randomisation
Participants will be centrally allocated to treatment groups (1:1) by a computer
generated dynamic procedure (minimisation) with a random component. Minimisation
will be performed on centre, surgical procedure and emergency status. Each
participant will be allocated with 80% probability to the group that minimises between
group differences in these factors among all participants recruited to the trial to date,
and to the alternative group with 20% probability.
To enter a patient into the Optimise trial, research staff at Site will log on to a secure
web-based randomisation system via a link on the ICNARC website
https://optimise.icnarc.org/ and complete the patient’s details to obtain a unique 4
digit patient number and allocation to a treatment group.
Trial interventions
The trial intervention period will commence at the start of general anaesthesia and
continue for six hours after surgery is completed (maximum total duration: 24 hours).
Peri-operative management for all patients
Care for all patients has been loosely defined to avoid extremes of clinical practice
but also practice misalignment.53 All patients will receive standard measures to
maintain oxygenation (SpO2 �94%), haemoglobin (>8 g/dl), core temperature (37 �C)
and heart rate (<100 bpm). 5% dextrose will be administered at 1 ml/kg/hr to satisfy
maintenance fluid requirements. An alternative maintenance fluid may be
administered (using the same rate of 1ml/kg/hr) at the discretion of the treating
clinician. Additional fluid will be administered at the discretion of the clinician guided
by pulse rate, arterial pressure, urine output, core-peripheral temperature gradient,
serum lactate and base excess.
Mean arterial pressure will be maintained between 60 and 100 mmHg using an alpha
adrenoceptor agonist or vasodilator as required. The trial interventions will
commence with induction of anaesthesia and continue until six hours after the end of
surgery. Post-operative analgesia will be provided by epidural infusion (bupivicaine
and fentanyl) or intra-venous infusion (morphine or fentanyl). If required, post-
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 18 1st December 2011
operative sedation will be provided with propofol or midazolam. Regular monitoring of
plasma potassium and glucose levels is recommended. The intervention period will
last a maximum of 24 hours (although in most cases much less than this).
Additional peri-operative management for the intervention group
This will commence from the induction of general anaesthesia and continue for six
hours following surgery. Cardiac output and stroke volume will be measured by
arterial waveform analysis (LiDCOrapid system). No more than 500ml of intra-venous
fluid will be administered prior to commencing cardiac output monitoring. The
manufacturer of the LiDCOrapid system (LiDCO Ltd, UK) will provide this technology
on loan to trial sites. In addition to the maintenance fluid and blood products
described previously, patients will receive 250ml fluid challenges with a colloid
solution as required in order to achieve a maximal value of stroke volume. The
absence of fluid responsiveness will be defined as the absence of a sustained rise in
stroke volume of at least 10% for 20 minutes or more (refer to the Optimise specific
SOP in your Investigator Site File for further guidance).
Patients in the intervention group will also receive dopexamine at a fixed rate of
0.5 �g/kg/min which will be commenced after fluid replacement has been initiated.
The dose of dopexamine will be reduced to 0.25 �g/kg/min if the heart rate increases
to greater than 120% of the baseline value or 100bpm (whichever is the greater) for
more than 30 minutes despite adequate anaesthesia and analgesia. If, despite dose
reduction, the heart rate does not decrease below this level, the dopexamine infusion
will be discontinued. All other management decisions will be taken by clinical staff.
Additional peri-operative management for the control group
Patients in the control group will be managed by clinical staff according to usual
practice. As described in the guidance for the management of all patients, this will
include 250ml fluid challenges with a colloid solution administered at the discretion of
the clinician guided by pulse rate, arterial pressure, urine output, core-peripheral
temperature gradient, serum lactate and base excess. If a specific haemodynamic
end-point for fluid challenges is to be used, the most appropriate would usually be a
sustained rise in central venous pressure of at least 2 mmHg for 20 minutes or more.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 19 1st December 2011
Cardiac output monitoring will not be routinely used in the control group unless
specifically requested by clinical staff.
Procedures to minimise bias
Optimise is a pragmatic effectiveness trial of a treatment algorithm. It is not possible
to conceal treatment allocation from all staff in trials of this type. However,
procedures will be put in place to minimise the possibility of bias arising because
research staff become aware of trial group allocation. Patients will be followed up for
complications by a member of research staff who is unaware of trial group allocation.
Complications will then be verified by the PI or designee at each site who will also be
unaware of trial group allocation. The principal investigator may nominate a senior
clinician to assist with this task if he/she becomes aware of the trial group allocation
of any individual patient. Research staff will be asked to confirm whether these
procedures have been complied with. The decision to admit a trial participant to a
critical care unit will be made by clinical staff and this decision must not be affected
by trial group allocation.
Data set collection
Randomisation data
� Full Name
� Date of Birth
� Gender
� Surgical procedure category
� Urgency of surgery / Elective or non-elective surgery
� Planned location following surgery
� Checklist to ensure patient meets eligibility criteria
� Pregnancy
Baseline data
� NHS Number/Hospital Number
� Weight
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 20 1st December 2011
� Residential Postcode
� Baseline Risk Factors
� ASA grade
� Quality of life according to EQ5D health status measure (see Appendix 5)
Measurements taken at 0, 6 hours and at end of trial period
� Surgery
o Start and end times of anaesthesia
o Surgical procedure performed
o Open or laparoscopic procedure
o ASA grade
o Anaesthetic technique
o Extubated at end of surgery (Y/N)
o Cardiac output monitor use
o Hours spent in recovery room
o Actual location following surgery
� Fluids
o Volume of intra-venous colloid solution during surgery
o Volume of intra-venous colloid solution during six hours after
surgery
o Volume of intra-venous crystalloid solution during surgery
o Volume of intra-venous crystalloid solution during six hours after
surgery
o Volume of blood products during surgery
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 21 1st December 2011
� Drugs
o Use of dopexamine (including start date/time and end date/time)
during intervention if applicable
o Dopexamine batch number
o Dopexamine rate, infusion concentration, total dose, infusion site
o Other drugs
o Post-operative epidural analgesia (Y/N)
� Research Staff
o Additional staff present to deliver intervention during surgery (Y/N)
o Additional staff present to deliver intervention during six hours after
surgery (Y/N)
Clinical outcomes
� 30 day post-operative complications (see Appendix 3)
� 30 day and 180 day post-operative mortality
� Post-Operative Morbidity Survey (POMS) for hospital in-patients on day 7
after surgery (see Appendix 4)
� 30 day post-operative infectious complications
� Duration of hospital stay
� 30 day post-operative critical care free days (alive and outside critical care)
� Quality of life according to EQ5D health status measure (30 and 180 days)
(see Appendix 5)
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 22 1st December 2011
Trial Drug
The trial drug or Investigational Medicinal Product (IMP) is presented as dopexamine
hydrochloride in a 1% solution (w/v). Each 5 ml ampoule contains 50 mg of
dopexamine hydrochloride.
Sourcing, manufacture and supply of IMP
Dopexamine hydrochloride has been commercially available for many years.
Cephalon Inc. is the current sole supplier of this agent which is manufactured in the
European Economic Area according to principles of Good Manufacturing Practice
(GMP). Cephalon Inc. are not the sponsors of this trial and the Optimise trial team
will not be responsible for auditing production or adherence to the principles of GMP.
Packaging, receipt, storage, dispensing and return of IMP
The IMP will be supplied individually to each site at a reduced price by Cephalon UK
Ltd, 1 Albany Place, Hyde Way, Welwyn Garden City, Hertfordshire, AL7 3BT, UK.
As this is an open trial which does not involve the use of placebo or dummy
infusions, no special measures are needed in terms of packaging or supply beyond
those routinely required.
The receipt, storage and dispensing of the IMP will be the responsibility of the
pharmacy department in each individual trial site. This will be performed in
accordance with accredited standards for routine pharmacy practice.
Any unused and unopened IMP ampoules will be returned to the pharmacy within
each individual site. Any IMP which remains unused having been dispensed and
diluted for administration will be disposed of in the clinical area according to the
policies of the individual trial sites. Where IMP is stored in clinical areas it will be
clearly labelled as such and stored in a separate locked area. Storage will comply
with local requirements and Good Clinical Practice (GCP) (i.e. temperature
monitoring etc).
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 23 1st December 2011
Prescription and labelling of IMP
The IMP will be prescribed and labelled as shown in Figure 1. The label will refer to
the information sheet for clinical staff which will be placed in the patient case notes to
provide basic information on the trial and contact details for the PI at the site.
Figure 1. Label for IMP storage box, prescription chart and syringe
Figure 2. Additional patient specific label for patient prescription chart and syringe
For Clinical Trials Use Only
Store below 25oC
Trial Name: Optimise
Sponsor: Queen Mary’s University of London, E1 2EF
EudraCT: 2009-009596-35 PI: _<INSERT NAME>____
Batch No : Supplier: Cephalon UK Ltd
Expiry Date:
Keep out of reach of children
For Clinical Trials Use Only
Please refer to clinical information sheet in medical notes
Store below 25oC
Dopexamine in dextrose IV infusion ______mg/ml
Date of preparation: Time of preparation:
Expiry Date: 24 hours from time of preparation
Patient Trial ID:
Keep out of reach of children
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 24 1st December 2011
Administration of IMP
As the dopexamine is reconstituted in dextrose for administration to the patient an
additional label (Figure 2) should be affixed to the prescription chart and syringe.
Dopexamine will be administered intravenously by infusion through a catheter in a
central or large peripheral vein at an initial rate of 0.5 �g/kg/min using a device which
provides accurate control of the rate of flow.
Contact with metal parts in infusion apparatus will be minimised. The drug will be
diluted in 5% dextrose solution at a concentration not exceeding 4 mg/ml when
administered via a central venous catheter or 1 mg/ml when administered via a
cannula in a large peripheral vein.
General precautions for use of dopexamine within the Optimise trial
There are a number of special warnings and precautions for use of dopexamine (see
Summary of Product Characteristics, SmPC for more details). Extensive experience
from clinical practice and clinical trials suggest that many of the potential adverse
effects of dopexamine are unlikely in this population at the dose intended for use.
Because of the vasodilator effects of dopexamine, correction of hypovolaemia (if
present) should be initiated at least 30 minutes prior to commencement of the
infusion.
Arterial pressure endpoints have been set for the use of vasopressors in patients
who are hypotensive. As with all high-risk surgical patients, care should also be taken
to avoid excessive sodium and fluid administration. All �2-adrenergic agonists may
depress plasma potassium and raise plasma glucose levels. These effects are minor
and reversible but it is advisable to monitor the potassium and glucose. Dopexamine
inhibits the uptake-1 mechanism and may potentiate the effects of exogenous
catecholamines such as noradrenaline. Dopexamine may induce a small reversible
decrease in circulating platelet numbers although no adverse effects attributable to
alterations in platelet count have been seen in clinical studies.
Dopexamine should be administered with caution to patients with a clinical history of
ischaemic heart disease especially following acute myocardial infarction or recent
episodes of angina pectoris. Benign arrhythmias and more rarely, serious
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 25 1st December 2011
arrhythmias have been reported. If excessive tachycardia occurs during dopexamine
administration, then a reduction or temporary discontinuation of the infusion should
be considered. The risk of thrombophlebitis and local necrosis may be increased if
the concentration of dopexamine administered via a peripheral vein exceeds
1 mg/ml.
IMP data collection in the Case Record Form
The Case Record Form (CRF) will ask for the following data on the IMP:
� batch number
� total dose received
� date/time infusion commenced
� date/time infusion discontinued
� primary safety endpoints
� rate of dopexamine administered
� infusion concentration
Prior and concomitant therapies
Data will be collected describing the recent or concomitant use of:
� intra-venous adrenergic agonists
� adrenergic antagonists
� monoamine oxidase inhibitors
Subject compliance monitoring
Administration of the IMP will only take place under the direct supervision of an
appropriately trained clinician or nurse in an operating theatre, post-anaesthetic
recovery unit or critical care unit. Alterations to the administered dose will be
recorded along with the reason for this change.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 26 1st December 2011
Predefined protocol deviations and violations
� Failure to administer dopexamine to an intervention group patient
� Administration of incorrect dose of dopexamine to an intervention group
patient
� Administration of dopexamine to a control group patient
� Use of cardiac output monitoring in a control group patient
Withdrawal of participants
The infusion will be discontinued or dose of dopexamine reduced if a patient
develops symptoms, signs or monitoring criteria suggestive of myocardial ischaemia
or tachycardia. In addition to adverse event reporting (see Safety and Adverse
Events section) where necessary, data collection and follow-up for participants for
such patients will be performed as normal. All randomised patients will be included in
the final analysis on an intention to treat basis.
Primary safety endpoints
Primary safety endpoints will be tachycardia, myocardial ischaemia and in patients
who receive the drug via a peripheral cannula, thrombophlebitis.
Dopexamine has been used for many years in critical care for similar indications to
that of the current trial. The drug has a good safety profile when used at a low dose
(0.5 �g/kg/min) in the patients eligible for participation in this trial (see inclusion and
exclusion criteria). This is particularly the case when administered with continuous
monitoring in a critical care area (as in this trial). Published data suggest that when
used at this dose and for this indication, dopexamine is not associated with any
increase in myocardial injury.34
Sample size calculation
The primary outcome for the trial is the number of patients developing post-operative
complications within 30 days following randomisation. In our previous interventional
trial, 68% of control group patients and 44% of GDHT patients developed
complications following surgery (relative risk 0.63 [0.46-0.87]; p=0.003). Assuming a
type I error rate of 5%, 345 patients per group (690 total) would be required to detect
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 27 1st December 2011
with 90% power a more conservative reduction in 30-day post-operative
complications from 50% in the control group to 37.5% in the intervention group
(absolute risk reduction 12.5%; relative risk reduction 25%). Allowing for a 3% one
way cross-over rate,35 this increases to 367 per group (734 total). Our experience
from previous trials indicates that loss to follow-up will be small. Sample size
calculations were performed using Stata 10.1 (StataCorp, College Station, TX).
Data from a recent national study of the high-risk surgical population suggests each
site will admit approximately 300 eligible patients each year.1 For this trial, thirty
patients per Site per year over two years will need to be recruited to meet the
recruitment target. In recent single-centre trials, as many as 100 patients have been
recruited in one year with less than 20% of patients refusing to participate.
Statistical analysis
Baseline demographic and clinical data for the two groups will be summarised but not
subjected to statistical testing. The primary effect estimate will be the relative risk of
30-day post-operative complications. For binary outcomes, differences between
groups will be tested using Fisher’s exact test. For continuous outcomes, differences
will be tested using independent samples, t-tests or non-parametric equivalents.
Logistic regression (for binary outcomes) and linear regression (for continuous
outcomes) will be used to perform analyses adjusted for baseline data. All analyses
will be performed on an intention to treat basis. Significance will be set at p<0.05.
Planned sub-group analyses
Outcome data will be analysed by urgency (elective vs non-elective) and surgical
procedure category. Sub-group analyses will be performed by testing for an
interaction between the sub-group categories and the treatment group in adjusted
(linear or logistic) regression models.
Interim analysis
A single interim analysis will be performed following the recruitment and follow-up to
30 days of 350 patients, and reviewed by the Data Monitoring and Ethics Committee
(DMEC). The interim analysis will be conducted using a Peto-Haybittle stopping rule
(P<0.001) to guide recommendations for early termination due to harm. The DMEC
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 28 1st December 2011
would be advised not to recommend stopping the trial at this stage due to
effectiveness, as any result in this number of patients would be unlikely to be
considered sufficiently definitive to change routine practice. Additional interim
analyses will be conducted only if required by the DMEC due to specific safety
concerns.
Safety and adverse events
Adverse Event (AE)
An AE is any untoward medical occurrence in a subject to whom a medicinal product
has been administered, including occurrences which are not necessarily caused by
or related to that product. An AE can therefore be any unfavourable and unintended
sign (including an abnormal laboratory finding), symptom or disease temporarily
associated with the use of IMP, whether or not considered related to the IMP.
Adverse Reaction (AR)
An AR is any untoward and unintended response in a subject to an IMP, which is
related to any dose administered to that subject. All adverse events judged by either
the reporting Investigator or the Sponsor as having a reasonable causal relationship
to a medicinal product qualify as adverse reactions. The expression reasonable
causal relationship means to convey in general that there is evidence or argument to
suggest a causal relationship.
Serious Adverse Event (SAE)
Any untoward medical occurrence that results in:
� death;
� is life-threatening;
� requires inpatient hospitalisation or prolongation of existing hospitalisation;
� results in persistent or significant disability/incapacity or
� is a congenital anomaly/birth defect (note pregnancy is a specific exclusion).
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 29 1st December 2011
Suspected Serious Adverse Reaction (SSAR)
An adverse reaction that is classed as serious and is consistent with the information
about dopexamine set out in the Summary of Product Characteristics (SmPC).
Suspected Unexpected Serious Adverse Reaction (SUSAR)
A suspected adverse reaction related to dopexamine that is both unexpected and
serious and is not consistant with the information set out in the Summary of Product
Characteristics (SmPC).
Expected adverse and serious adverse events
The incidence of post-operative complications in the trial population is widely
reported as very high, ranging from 45-70%. The majority of such complications can
be clearly regarded as expected complications of surgery. Such expected adverse
and serious adverse events will be recorded both locally and on the Optimise web
portal. Expected complications of surgery will be reported on an individual basis if:
1. they are deemed to be life-threatening, to have caused a congenital
anomaly/birth defect or
2. have resulted in death.
Expected complications of surgery:
Acute kidney injury
Acute respiratory distress syndrome
Anastamotic breakdown
Gastro-intestinal bleed
Laboratory confirmed bloodstream infection
Nosocomial pneumonia
Post-operative haemorrhage
Pulmonary embolism
Pleural effusions
Paralytic ileus
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 30 1st December 2011
Surgical site infection
Sepsis, severe sepsis and septic shock
Stroke
Transient ischaemic attack
Urinary tract infection
The following are not expected complications of surgery and will require reporting if they meet SAE criteria as defined on page 27 (N.B. Please note, this list is not exhaustive):
Acute psychosis
Anaphylaxis
Arrhythmia
Bowel infarction
Cardiogenic pulmonary oedema
Cardiac or respiratory arrest
Limb or digital ischaemia
Multi-organ dysfunction syndrome
Myocardial ischaemia or infarction
Recording and documenting of Adverse Events (AEs)
The research team at Sites will be responsible for recording AEs observed during the
30-day trial period. These will be verified by the PI at each site prior to entry onto the
CRF. The Adverse Event report page in the CRF will be completed as applicable.
AEs must be recorded as defined in the CRF, regardless of relationship to trial drug
as determined by the PI. The PI should attempt, if possible, to establish a diagnosis
based on the subject’s signs and symptoms. When a diagnosis for the reported signs
or symptoms is known, the PI should report the diagnosis as the adverse event,
rather than reporting the individual symptoms. The PI must assess causality for any
AEs. The PI should follow all AEs observed during the trial until they are resolved or
stabilised, or the events are otherwise explained. AEs are recorded at each trial time
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 31 1st December 2011
point and tabulated for inclusion in an annual report to the Sponsor, Medicines and
Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee
(REC). SUSARs will be recorded and reported in line with UK statutory requirements
for clinical trials involving IMP.
Pharmacovigilance reporting (SAE and SUSAR)
Where the reporting of an SAE (or SAR or SUSAR) is required, the PI at each site
should e-mail the SAE reporting form to the Chief Investigator at Barts and The
London School of Medicine and Dentistry at the following address:
If it is not possible to e-mail the SAE to the Chief Investigator, this may be sent by fax
with: “SAE for review, for the urgent attention of Dr Rupert Pearse, Optimise Chief
Investigator” to the following number:
Fax: 020 7377 7299 (Intensive Care Research Office, Royal London Hospital)
The Chief Investigator (CI) will check that all fields have been completed and that
the form has been signed by the PI at that site. The CI will not down grade SAEs or SUSARs from the treating PI at the site. However the CI can upgrade an AE to
a SAE or a SAE to a SUSAR. The CI will then fax the completed SAE form within
24hrs of becoming aware of the event, to the R&D office at Barts and The London
School of Medicine and Dentistry who will maintain records in accordance with the
responsibilities of the Sponsor and will also be responsible for expedited reporting to
the MHRA. Annual Safety Reports will be provided by ICNARC CTU to the MHRA,
REC and R&D office at Barts and The London School of Medicine and Dentistry for
every year that the trial is running.
Pharmacovigilance Standard Operating Procedures (SOPs) will indicate the required
process for reporting of SAE and SUSARs. In brief, these will be logged via the
electronic CRF and copies e-mailed to ICNARC CTU, the R&D office at Barts and
The London School of Medicine and Dentistry and the local R&D office for the trial
site. The PI at each site will nominate a designee to sign the SAE and SUSAR
reports in their absence.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 32 1st December 2011
Economic analysis
Retrospective economic analyses suggest that the intervention may reduce
healthcare costs.51, 52 A prospective economic analysis will encourage rapid
implementation of the findings of this trial. Cost-effectiveness of peri-operative
cardiovascular management will be evaluated in two phases.
Phase I: A within-trial economic analysis using prospectively collected clinical and
resource use data. Cost estimation will be performed from an NHS perspective using
individual patient-level data. Information on resource use will include duration of
hospital stay, critical care resource use, concomitant medications, interventions,
infusions and investigations for initial hospitalisation, associated complications and
re-hospitalisations. Representative national unit costs will be estimated from routine
and published literature (e.g. NHS reference costs, etc). The additional cost of the
intervention will be assessed using information on the additional resources required
to administer the intervention in a critical care unit or post-anaesthetic recovery unit,
in addition to the use of fluid, drugs and disposables. The main outcome for this
analysis will be the Quality Adjusted Life Year (QALY), which will be assessed using
the EuroQoL-5D (EQ-5D) questionnaire.
Phase II: This part of the trial will address the need to extrapolate beyond the trial
trial period and assess the cost effectiveness of the treatment strategies being
investigated within the broader perspective of the NHS.51 An economic model will be
developed to predict long term outcomes and costs. Overall cost-effectiveness will be
expressed in terms of additional cost per QALY gained. Uncertainty in cost-
effectiveness will be presented in terms of the probability that alternative forms of
management are most cost-effective given a range of maximum values the NHS
might be willing to pay for an additional QALY.36 Trial data will provide estimates of
costs and effects that initially follow clinical outcome data.
To account for long-term costs and benefits of the alternative treatments it will be
necessary to extrapolate beyond the trial period. Data from this trial will be combined
with that of other relevant trials to facilitate a comparison of alternative approaches to
peri-operative cardiovascular management.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 33 1st December 2011
To inform future research priorities in the NHS, Bayesian value of information
analysis will be used to determine the expected costs of decision uncertainty and the
value that can be placed on additional research aimed at reducing this uncertainty.51
Sub-studies
Biological sub-study
In selected participating sites which have agreed to do so, blood and urine samples
will taken before surgery and then at 24 and 72 hours after the start of the
intervention period. Blood samples will be centrifuged within 30 minutes of collection
to extract plasma which will be divided and placed in three storage tubes for each
patient, clearly labelled and stored in a -80�C freezer. The selected participating sites
will be assessed prior to the start of the study to ensure they have the necessary
facilities to collect and store the blood and urine samples. Urine samples will be
divided and placed in two storage tubes for each patient, clearly labelled and stored
in a -80�C freezer. The PI will ensure that all the research staff required to collect and
store samples have been adequately trained to do so.
It is anticipated, every six months (depending on recruitment rate), samples will be
transferred (by Dr. Rupert Pearse and his research team at Barts and The London
School of Medicine & Dentistry) on dry ice to a central laboratory at Barts and The
London School of Medicine & Dentistry for storage in a -80�C freezer until analyses
are performed. Material Transfer Agreements between sites will be put in place
where required to ensure compliance with the Human Tissue Act. Sample analysis
will include markers of myocardial injury (B-type natriuretic peptide and troponin I),
acute kidney injury (N-GAL and creatinine) and inflammatory markers (Il-1, Il-6, Il-10,
TNF�, C-reactive protein). In addition, plasma and urine will be stored for a maximum
of 10 years from the end of the trial to allow further analyses of direct relevance to
this field of research. Additional ethics approval will be sought for such analyses.
Laboratory sample analysis contact: Dr Rupert Pearse,
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 34 1st December 2011
Barts and The London School of Medicine &
Dentistry
0207 377 7299
Markers of pre-load responsiveness sub-study
In selected participating sites which have agreed to do so, additional data will be
collected regarding the predictive accuracy of a range of ‘dynamic’ markers of
preload responsiveness. These variables define the proportional change in global
haemodynamics which occurs during the respiratory cycle. The LiDCOrapid monitor
automatically calculates the following variables: pulse pressure variation (%), stroke
volume variation (%) and systolic pressure variation (%). Implementation of the
findings of the Optimise trial may be improved by a better understanding of the
predictive accuracy of these variables.
For patients who are monitored using the LiDCOrapid monitor, sites participating in
this sub-study will collect the following additional data during the sixty seconds before
and after each of three 250ml colloid fluid challenges during surgery and each of
three 250ml colloid fluid challenges after surgery:
� Pulse rate
� Mean arterial pressure
� Cardiac index (nominal value)
� Stroke volume (nominal value)
� Central venous pressure (if available)
� Pulse pressure variation (%)
� Stroke volume variation (%)
� Systolic pressure variation (%)
This sub-study is observational and will not result in any change in clinical
management.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 35 1st December 2011
Pre-load responsiveness sub-study contact: Dr Rupert Pearse,
Barts and The London School of Medicine &
Dentistry
0207 377 7299
End of trial and stopping rules
The end of the trial will be defined as the end of the 30-day period of follow-up for the
final participant in the trial. Interim analyses will be performed at pre-defined stages
by the DMEC. Early termination of trial in response to safety issues will be addressed
via the DMEC. They will report any issues pertaining to safety to the CI, who will be
responsible for informing the Sponsor and will take appropriate action to halt the trial
if concerns exist about participant safety. In keeping with GCP guidelines as
Sponsor, the relevant institutions will be responsible for source data verification.
The Main Research Ethics Committee will be notified in writing if the trial has been
concluded or terminated early.
Data storage
Data will be transcribed on to the CRF prior to entry on to the secure Optimise data
entry web portal. Submitted data will be reviewed for completeness and consistency.
Data will be stored securely against unauthorised manipulation and accidental loss
as only authorised users at site or at ICNARC CTU will have access. Desktop
security is maintained through user names and frequently updated passwords and
back up procedures are in place. Storage and handling of confidential trial data and
documents will be in accordance with the Data Protection Act 1998.
Confidentiality
The patient’s full name, date of birth, hospital number and NHS number will be
collected at randomisation to allow tracing through national records. The personal
data recorded on all documents will be regarded as confidential.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 36 1st December 2011
The PI must maintain in strict confidence trial documents, which are to be held in the
local hospital (e.g. patients' written consent forms). The PI must ensure the patient's
confidentiality is maintained at all times.
ICNARC CTU together with Queen Mary’s University of London will maintain the
confidentiality of all subject data and will not reproduce or disclose any information by
which subjects could be identified, other than reporting of serious adverse events.
Representatives of the trial team will be required to have access to
patient notes for quality assurance purposes but patients should be reassured that
their confidentiality will be respected at all times. In the case of special problems
and/or competent authority queries, it is also necessary to have access to the
complete trial records, provided that patient confidentiality is protected.
For central (180 day) follow-up of patients the NHS Medical Information Research
Service (MRIS) will be used to trace patients (this will be completed by the Optimise
trial team).
Archiving
All trial documentation and data will be archived centrally at Queen Mary's University
of London and ICNARC CTU in a purpose designed archive facility for twenty years
in conformance with the applicable regulatory requirements. Access to these
archives will be restricted to authorised personnel. Electronic data sets will be stored
indefinitely.
Trial monitoring, audit and inspection
The Sponsor will have oversight of the trial conduct at each site. The trial team will
take day to day responsibility for ensuring compliance with the requirements of GCP
in terms of quality control and quality assurance of the data collected as well as IMP
management and pharmacovigilance.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 37 1st December 2011
The Optimise Trial Management Group will communicate closely with individual sites
and the Sponsor’s representatives to ensure these processes are effective.
A Data Monitoring and Ethics Committee (DMEC) is in place. The committee is
independent of the trial team and comprises of two clinicians with experience in
undertaking clinical trials and a statistician. The DMEC agree conduct and remit,
which will include the early termination process. The DMEC review the trial data at
regular intervals and request interim analyses of efficacy as it sees fit. The DMEC
functions primarily as a check for safety by reviewing adverse events (Details of the
DMEC can be found on page 40-41).
Monitoring safety and well being of trial participants
The Research and Development departments at each trial site perform regular audits
of research practice. Systems are in place to ensure that all PIs and designees are
able to demonstrate that they are qualified by education, training or experience to
fulfil their roles and that procedures are in place which can assure the quality of every
aspect of the trial. Because the entire protocol will last less than twelve hours in most
cases, it is extremely unlikely that new safety information will arise during the
intervention period. Nonetheless should this situation arise, then trial participants will
be informed and asked if they wish to continue in the trial. If the subjects wish to
continue in the trial they will be formally asked to sign a revised approved patient
information sheet and consent form.
Early termination of trial in response to safety issues will be addressed via the
DMEC. Day to day management will be undertaken via a Trial Management Group
composed of the Chief Investigator and supporting staff. They will meet on a regular
basis to discuss trial issues. Site monitoring will be directed by the Optimise Trial
Management Group based at ICNARC CTU.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 38 1st December 2011
Monitoring safety of Investigators
Each site has health and safety policies for employees. All personnel should also
ensure they adhere to any health and safety regulations relating to their area of work.
The PI will ensure that all personnel have been trained appropriately to undertake
their specific tasks. The trial team will complete GCP and consent training prior to
start up.
Ethical considerations
The PI will ensure that this trial is conducted in accordance with the Principles of the
Declaration of Helsinki as amended in Tokyo (1975), Venice (1983), Hong Kong
(1989), South Africa (1996) and Edinburgh (2000) as described at the following
internet site: http://www.wma.net/e/policy/b3.htm. The trial will fully adhere to the
principles outlined in the Guidelines for Good Clinical Practice ICH Tripartite
Guideline (January 1997).
At sites, all accompanying material given to a potential participant will have
undergone an independent Ethics Committee review in the UK. Full approval by the
Ethics Committee has been obtained prior to starting the trial and fully documented
by letter to the Chief Investigator naming the trial site, local PI (who may also be the
Chief Investigator) and the date on which the ethics committee deemed the trial as
permissible at that site.
Trial sponsorship and indemnity
Queen Mary University of London will act as Sponsor and provide no fault insurance
for this trial.
Trial Management
The trial management will be conducted by the Optimise Trial Management Group
and the ICNARC CTU.
Trial Steering Committee (TSC)
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 39 1st December 2011
A Trial Steering Committee, consisting of several independent clinicians and trialists
lay representation, co-investigators and an independent Chair, will oversee the trial.
Face to face meetings will be held at regular intervals determined by need but not
less than once a year.
The TSC will take responsibility for:
� approving the final trial protocol;
� major decisions such as a need to change the protocol for any reason;
� monitoring and supervising the progress of the trial;
� reviewing relevant information from other sources;
� considering recommendations from the DMEC and
� informing and advising on all aspects of the trial.
The membership of the TSC is:
Independent chair:
Prof Tim Coats, Professor of Emergency Medicine, University of Leicester
Independent members:
Dr Geoff Bellinghan, Director of Critical Care, University College London
Mr Dileep Lobo, Senior Lecturer in Surgery, Nottingham University
Ms Lisa Hinton, Lay Member, DIPEx Health Experiences Research Group
Department of Primary Health Care, University of Oxford
Non-independent members:
Prof David Bennett, Prof Charles Hinds, Dr Rupert Pearse, Prof Kathy Rowan, Aoife
Ahern, Dr David Harrison, Dr Rachael Scott, observer from Queen Marys University
of London and a representative of the National Institute for Health Research.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 40 1st December 2011
Data Monitoring and Ethics Committee (DMEC)
The Data Monitoring and Ethics Committee will consist of independent experts with
relevant clinical research and statistical experience. During the period of recruitment
into the trial, interim analyses of the accumulating data will be supplied, in strict
confidence, to the DMEC, along with any other analyses that the committee may
request. The frequency of these analyses will be determined by the committee.
The membership of the DMEC is:
Independent chair:
Dr Simon Gates, Principal Research Fellow, University of Warwick.
Prof Danny McAuley, Senior Lecturer and Consultant in Intensive Care Medicine,
The Queen’s University of Belfast.
Prof Tom Treasure, Professor of Cardiothoracic Surgery, University College London.
Funding
This trial is jointly funded by a National Institute for Health Research Clinician
Scientist Award held by Dr Rupert Pearse and ICNARC CTU.
LiDCO will be providing machines on loan including consumables (for trial
participants only) free of charge to each site for the duration of the trial.
The IMP will be supplied individually to each site at a reduced price by Cephalon UK
Ltd.
(N.B. LiDCO and Cephalon had no input in the production of this protocol).
Publication
Data arising from the research will be made available to the scientific community in a
timely and responsible manner. A detailed scientific report will be submitted to a
widely accessible scientific journal on behalf of the Optimise Trial Management
Group. The TSC will agree the membership of a writing committee which will take
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 41 1st December 2011
primary responsibility for final data analysis and authorship of the scientific report. All
authors will comply with internationally agreed requirements for authorship and will
approve the final manuscript prior to submission.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 42 1st December 2011
References
1. Pearse RM, Harrison DA, James P, et al. Identification and characterisation of the high-risk surgical population in the United Kingdom. Crit Care 2006;10(3):R81.
2. Jhanji S, Thomas B, Ely A, Watson D, Hinds CJ, Pearse RM. Mortality and utilisation of critical care resources amongst high-risk surgical patients in a large NHS trust. Anaesthesia 2008; 63: 695-700.
3. Cullinane M, Gray AJ, Hargraves CM, Lansdown M, Martin IC, Schubert M. The 2003 Report of the National Confidential Enquiry into Peri-Operative Deaths. London: NCEPOD, 2003.
4. Campling EA, Devlin HB, Lunn JN. Report of the National Confidential Enquiry into Peri-Operative Deaths. London: NCEPOD, 1990.
5. Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg 2005;242(3):326-41.
6. Clowes GH, Del Guercio LR. Circulatory response to trauma of surgical operations. Metabolism 1960:67-81.
7. Shoemaker WC, Montgomery ES, Kaplan E, Elwyn DH. Physiologic patterns in surviving and nonsurviving shock patients. Use of sequential cardiorespiratory variables in defining criteria for therapeutic goals and early warning of death. Arch Surg 1973;106(5):630-6.
8. Kusano C, Baba M, Takao S, et al. Oxygen delivery as a factor in the development of fatal postoperative complications after oesophagectomy. Br J Surg 1997;84(2):252-7.
9. Peerless JR, Alexander JJ, Pinchak AC, Piotrowski JJ, Malangoni MA. Oxygen delivery is an important predictor of outcome in patients with ruptured abdominal aortic aneurysms. Ann Surg 1998;227(5):726-732.
10. Poeze M, Ramsay G, Greve JW, Singer M. Prediction of postoperative cardiac surgical morbidity and organ failure within 4 hours of intensive care unit admission using esophageal Doppler ultrasonography. Crit Care Med 1999;27(7):1288-94.
11. Pearse RM, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Changes in central venous saturation after major surgery, and association with outcome. Crit Care 2005;9:R694-R699.
12. Mythen MG, Webb AR. Perioperative plasma volume expansion reduces the incidence of gut mucosal hypoperfusion during cardiac surgery. Arch Surg 1995;130(4):423-429.
13. Gan TJ, Soppitt A, Maroof M, et al. Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. Anesthesiology 2002;97(4):820-6.
14. Noblett SE, Snowden CP, Shenton BK, Horgan AF. Randomized clinical trial assessing the effect of Doppler-optimized fluid management on outcome after elective colorectal resection. Br J Surg 2006;93(9):1069-76.
15. Wakeling HG, McFall MR, Jenkins CS, et al. Intraoperative oesophageal Doppler guided fluid management shortens postoperative hospital stay after major bowel surgery. Br J Anaesth 2005;95(5):634-42.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 43 1st December 2011
16. Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial [ISRCTN38797445]. Crit Care 2005;9(6):R687-93.
17. McKendry M, McGloin H, Saberi D, Caudwell L, Brady AR, Singer M. Randomised controlled trial assessing the impact of a nurse delivered, flow monitored protocol for optimisation of circulatory status after cardiac surgery. BMJ 2004;329(7460):258.
18. Polonen P, Ruokonen E, Hippelainen M, Poyhonen M, Takala J. A prospective, randomized study of goal-oriented hemodynamic therapy in cardiac surgical patients. Anesth Analg 2000;90(5):1052-9.
19. Berlauk JF, Abrams JH, Gilmour IJ, O'Connor SR, Knighton DR, Cerra FB. Preoperative optimization of cardiovascular hemodynamics improves outcome in peripheral vascular surgery. A prospective, randomized clinical trial. Ann Surg 1991;214(3):289-97; discussion 298-9.
20. Boyd O, Grounds RM, Bennett ED. A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. JAMA 1993;270(22):2699-707.
21. Wilson J, Woods I, Fawcett J, et al. Reducing the risk of major elective surgery: randomised controlled trial of preoperative optimisation of oxygen delivery. BMJ 1999;318(7191):1099-103.
22. Lobo SM, Salgado PF, Castillo VG, et al. Effects of maximizing oxygen delivery on morbidity and mortality in high-risk surgical patients. Crit Care Med 2000;28(10):3396-404.
23. Ueno S, Tanabe G, Yamada H, et al. Response of patients with cirrhosis who have undergone partial hepatectomy to treatment aimed at achieving supranormal oxygen delivery and consumption. Surgery 1998;123(3):278-86.
24. Bender JS, Smith-Meek MA, Jones CE. Routine pulmonary artery catheterization does not reduce morbidity and mortality of elective vascular surgery: results of a prospective, randomized trial. Ann Surg 1997;226(3):229-36.
25. Valentine RJ, Duke ML, Inman MH, et al. Effectiveness of pulmonary artery catheters in aortic surgery: a randomized trial. J Vasc Surg 1998;27(2):203-11; discussion 211-2.
26. Ziegler DW, Wright JG, Choban PS, Flancbaum L. A prospective randomized trial of preoperative "optimization" of cardiac function in patients undergoing elective peripheral vascular surgery. Surgery 1997;122(3):584-92.
27. Bonazzi M, Gentile F, Biasi GM, et al. Impact of perioperative haemodynamic monitoring on cardiac morbidity after major vascular surgery in low risk patients. A randomised pilot trial. Eur J Vasc Endovasc Surg 2002;23(5):445-51.
28. Conway DH, Mayall R, Abdul-Latif MS, Gilligan S, Tackaberry C. Randomised controlled trial investigating the influence of intravenous fluid titration using oesophageal Doppler monitoring during bowel surgery. Anaesthesia 2002;57(9):845-9.
29. Fenwick E, Wilson J, Sculpher M, Claxton K. Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: a cost-effectiveness analysis. Intensive Care Med 2002;28(5):599-608.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 44 1st December 2011
30. Guest JF, Boyd O, Hart WM, Grounds RM, Bennett ED. A cost analysis of a treatment policy of a deliberate perioperative increase in oxygen delivery in high risk surgical patients. Intensive Care Med 1997;23(1):85-90.
31. Walsh SR, Tang T, Bass S, Gaunt ME. Doppler-guided intra-operative fluid management during major abdominal surgery: systematic review and meta-analysis. Int J Clin Pract 2008;62(3):466-70.
32. Abbas SM, Hill AG. Systematic review of the literature for the use of oesophageal Doppler monitor for fluid replacement in major abdominal surgery. Anaesthesia 2008;63(1):44-51.
33. Pearse RM, Belsey JD, Cole JN, Bennett ED. Effect of dopexamine infusion on mortality following major surgery: individual patient data meta-regression analysis of published clinical trials. Crit Care Med 2008;36(4):1323-9.
34. Pearse RM, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett D. The incidence of myocardial injury following post-operative Goal Directed Therapy. BMC Cardiovasc Disord 2007;7:10.
35. Pearse RM, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial. Crit Care 2005;9:R687-R693.
36. Fenwick E, Claxton K, Sculpher M. Health Econ 2001;10(8):779-87.
37. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007;116(17):1971-96.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 45 1st December 2011
Appendix 1: Definition of post-operative complications
Myocardial ischaemia or infarction
Acute ECG changes with appropriate clinical findings and changes in cardiac
troponins.
Arrhythmia
ECG evidence of rhythm disturbance resulting in a fall in mean arterial pressure of
greater than 20% and considered by clinical staff to be severe enough to require
treatment (anti-arrhythmic agents, vasoactive agents, intra venous fluid, etc).
Cardiac or respiratory arrest
Clinical criteria according to UK Resuscitation Council Guidelines.
Limb or digital ischaemia
Sustained loss of arterial pulse (as determined by palpation or Doppler) or obvious
gangrene.
Cardiogenic pulmonary oedema
Appropriate clinical history and examination with consistent chest radiograph.
Pulmonary embolism
Computed tomography (CT) pulmonary angiogram with appropriate clinical history.
Acute respiratory distress syndrome
According to consensus criteria:
i) suitable precipitating condition (many causes exist);
ii) acute onset diffuse bilateral pulmonary infiltrates on chest radiograph;
iii) no evidence of cardiac failure or fluid overload (PAOP < 18 mmHg);
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 46 1st December 2011
iv) Either:
a) PaO2:FiO2 < 40 kPa = Acute Lung InjuryPaO2:FiO2 < 27 kPa =
Acute Respiratory Distress Syndrome.
Gastro-intestinal bleed
Unambiguous clinical evidence or endoscopy showing blood in gastro-intestinal tract.
Bowel infarction
Demonstrated at laparotomy.
Anastamotic breakdown
Demonstrated at laparotomy or by contrast enhanced radiograph or CT scan.
Paralytic ileus
Persistent clinical evidence of intestinal ileus and failure to tolerate enteral fluid or
feed associated with valid cause.
Acute kidney injury
A two-fold increase in serum creatinine or sustained oliguria of < 0.5 ml kg-1 hour-1 for
twelve hours (consensus definition).
Infection, source uncertain
Two more of the following associated with strong clinical suspicion of infection
(sufficient to require intra-venous antibiotic therapy, etc):
i) core temperature <36 �C or >38 �C
ii) white cell count >12 x 109 l-1 or <4 x 109 l-1
iii) respiratory rate >20 breaths per minute or PaCO2 < 4.5 kPa
iv) pulse rate >90 bpm
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 47 1st December 2011
Multi-organ dysfunction syndrome
A life threatening but potentially reversible physiologic derangement involving failure
of two or more organ systems not involved in the primary underlying disease
process.
Acute psychosis
Acute episode of severe confusion or personality change which may result in
hallucinations or delusional beliefs in the absence of a pre-existing diagnosis which
may account for the clinical symptoms and signs.
Urinary tract infection
A symptomatic urinary tract infection must meet at least one of the following criteria:
i) Patient has at least one of the following signs or symptoms with no other
recognized cause: fever (>38 �C), urgency, frequency, dysuria, or
suprapubic tenderness
and
Patient has a positive urine culture, that is, >105 microorganisms per cm3
of urine with no more than two species of microorganisms.
ii) Patient has at least two of the following signs or symptoms with no other
recognized cause: fever (>38 �C), urgency, frequency, dysuria, or supra-
pubic tenderness and at least one of the following:
a. positive dipstick for leucocyte esterase and/or nitrate;
b. pyuria (urine specimen with >10 WBC mm-3);
c. organisms seen on Gram stain of unspun urine;
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 48 1st December 2011
d. at least two urine cultures with repeated isolation of the same
uropathogen with >102 colonies/ mL in nonvoided specimens;
e. >105 colonies/mL of a single uropathogen in a patient being treated
with an effective antimicrobial agent for a urinary tract infection;
f. physician diagnosis of a urinary tract infection;
g. physician institutes appropriate therapy for a urinary tract infection.
Other infections of the urinary tract (kidney, ureter, bladder, urethra, etc)
Other infections of the urinary tract must meet at least one of the following criteria:
i) Patient has organisms isolated from culture of fluid (other than urine) or
tissue from affected site.
ii) Patient has an abscess or other evidence of infection seen on direct
examination, during a surgical operation, or during a histopathologic
examination.
iii) Patient has at least two of the following signs or symptoms with no other
recognized cause: fever (>38 �C), localized pain, or localized tenderness
at the involved site and at least one of the following:
a. purulent drainage from affected site;
b. organisms cultured from blood that are compatible with suspected site of
infection;
c. radiographic evidence of infection, for example, abnormal ultrasound,
computed tomography or magnetic resonance imaging;
d. physician diagnosis of infection of the kidney, ureter, bladder, urethra, or
tissues surrounding the retroperitoneal or perinephric space;
e. physician institutes appropriate therapy for an infection of the kidney,
ureter, bladder, urethra, or tissues surrounding the retroperitoneal or
perinephric space.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 49 1st December 2011
Surgical site infection SSI (superficial incisional)
A superficial SSI must meet the following criteria:
i) Infection occurs within 30 days after the operative procedure and involves
only skin and subcutaneous tissue of the incision and patient has at least
one of the following:
a. purulent drainage from the superficial incision;
b. organisms isolated from an aseptically obtained culture of fluid or tissue
from the superficial incision;
c. at least one of the following signs or symptoms of infection: pain or
tenderness, localized swelling, redness, or heat, and superficial incision is
deliberately opened by surgeon, unless incision is culture-negative;
d. diagnosis of superficial incisional SSI by the surgeon or attending
physician.
Surgical site infection (deep incisional)
A deep incisional SSI must meet the following criteria:
i) Infection occurs within 30 days after the operative procedure if no implant
is left in place or within 1 year if implant is in place and the infection
appears to be related to the operative procedure and involves deep soft
tissues (e.g., fascial and muscle layers) of the incision and patient has at
least one of the following:
a. purulent drainage from the deep incision but not from the organ/space
component of the surgical site;
b. a deep incision spontaneously dehisces or is deliberately opened by a
surgeon when the patient has at least one of the following signs or
symptoms: fever (>38C) or localized pain or tenderness, unless incision is
culture-negative;
c. an abscess or other evidence of infection involving the deep incision is
found on direct examination, during reoperation, or by histopathologic or
radiologic examination;
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 50 1st December 2011
d. diagnosis of a deep incisional SSI by a surgeon or attending physician.
An infection that involves both superficial and deep incision sites should be classified
as a deep incisional SSI.
Surgical site infection (organ/space)
An organ/space SSI involves any part of the body, excluding the skin incision, fascia,
or muscle layers, that is opened or manipulated during the operative procedure.
Specific sites are assigned to organ/space SSI to further identify the location of the
infection. Listed later are the specific sites that must be used to differentiate
organ/space SSI. An example is appendectomy with subsequent subdiaphragmatic
abscess, which would be reported as an organ/space SSI at the intraabdominal
specific site. An organ/space SSI must meet the following criteria:
i) Infection occurs within 30 days after the operative procedure if no implant
is left in place or within 1 year if implant is in place and the infection
appears to be related to the operative procedure and infection involves
any part of the body, excluding the skin incision, fascia, or muscle layers,
that is opened or manipulated during the operative procedure and patient
has at least one of the following:
a. purulent drainage from a drain that is placed through a stab wound into
the organ/space;
b. organisms isolated from an aseptically obtained culture of fluid or tissue in
the organ/ space;
c. an abscess or other evidence of infection involving the organ/space that is
found on direct examination, during reoperation, or by histopathologic or
radiologic examination;
d. diagnosis of an organ/space SSI by a surgeon or attending physician.
Laboratory - confirmed bloodstream infection
Laboratory - confirmed bloodstream infection must meet at least one of the following
criteria:
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 51 1st December 2011
i) Patient has a recognized pathogen cultured from one or more blood
cultures and the organism cultured from blood is not related to an
infection at another site.
ii) Patient has at least one of the following signs or symptoms:
fever (>38�C), chills, or hypotension and at least one of the following:
a. common skin contaminant is cultured from two or more blood cultures
drawn on separate occasions;
b. common skin contaminant is cultured from at least one blood culture
from a patient with an intravascular line, and the physician institutes
appropriate antimicrobial therapy;
c. positive antigen test on blood.
And signs and symptoms and positive laboratory results are not related to
an infection at another site.
Nosocomial pneumonia
Ventilator-associated pneumonia (i.e. pneumonia in persons who had a device to
assist or control respiration continuously through a tracheostomy or by endotracheal
intubation within the 48-hour period before the onset of infection) will be classified
separately. Care will be taken to distinguish between tracheal colonization, upper
respiratory tract infections and early onset pneumonia. Nosocomial pneumonia will
be characterized as early or late onset ie before or after first 4 days of hospitalization.
Where repeated episodes of nosocomial pneumonia are suspected, a combination of
new signs and symptoms and radiographic evidence or other diagnostic testing will
be required to distinguish a new episode from a previous one. This category
includes ventilator-associated pneumonia (i.e. pneumonia in persons who had a
device to assist or control respiration continuously through a tracheostomy or
endotracheal tube), however care will be taken to distinguish between tracheal
colonization, upper respiratory tract infections and early onset pneumonia.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 52 1st December 2011
Nosocomial pneumonia must meet the following criteria:
i) Two or more serial chest radiographs with at least one of the following:
a. new or progressive and persistent infiltrate;
b. consolidation;
c. cavitation.
And at least one of the following:
a. fever (>38°C) with no other recognized cause;
b. leucopaenia (<4,000 WBC mm-3) or leucocytosis (>12,000 WBC mm-3)
c. for adults >70 years old, altered mental status with no other
recognized cause.
And at least two of the following:
a. new onset of purulent sputum or change in character of sputum, or
increased respiratory secretions, or increased suctioning requirements
b. new onset or worsening cough, or dyspnoea, or tachypnoea;
c. rales or bronchial breath sounds;
d. worsening gas exchange
Post-operative haemorrhage
Overt blood loss requiring transfusion of two or more units of blood in two hours.
Stroke
Clinical diagnosis with confirmation by CT scan.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 53 1st December 2011
Appendix 2: Classification of urgency of surgery
Elective: At a time to suit both patient and surgeon or within 3 weeks if more urgent.
Non-elective: Within 24 hours of the decision that surgery is required.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 54 1st December 2011
Appendix 3: Risk factors for cardiac or respiratory disease
Examples include:
� Exercise tolerance equivalent to six metabolic equivalents (METs) or less as
defined by ACC/AHA guidelines;37
� Past medical history of ischaemic heart disease (angina, myocardial infarction or
acute coronary syndrome);
� Angiographically proven ischaemic heart disease;
� Ejection fraction less than 30% (echocardiography);
� Moderate or severe valvular heart disease;
� Clear history or clinical signs of heart failure (requiring treatment, oedema, etc);
� Clinical history indicative of Chronic Obstructive Pulmonary Disease (COPD) ie
chronic productive cough for at least three months of two consecutive years;
� Poor lung function demonstrated by spirometry (FEV1 or FVC <75% predicted);
� Radiographically confirmed chronic lung disease (fibrosis, COPD, etc);
� Anaerobic threshold �14 ml min-1 kg-1 on sub-maximal exercise testing;
� Heavy smoker.
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 55 1st December 2011
Appendix 4: Post-operative morbidity survey (POMS)
Morbidity Criteria Data source
Cardiovascular
Diagnostic tests or therapy within the last 24 hr for any of
the following: new myocardial infarction or ischemia,
hypotension (requiring fluid therapy >200 ml/hr or
pharmacological therapy), atrial or ventricular arrhythmias,
cardiogenic pulmonary oedema, thrombotic event (requiring
anticoagulation).
Treatment chart
Note review
Pulmonary Has the patient developed a new requirement for oxygen or
respiratory support.
Patient observation
Treatment chart
Infectious Currently on antibiotics and/or has had a temperature of
>38°C in the last 24 hr
Treatment chart
Observation chart
Renal Presence of oliguria <500 ml/24 hr; increased serum
creatinine (>30% from preoperative level); urinary catheter
in situ.
Fluid balance chart
Biochemistry result
Patient observation
Gastrointestinal Unable to tolerate an enteral diet for any reason including
nausea, vomiting, and abdominal distension (use of anti-
emetic).
Patient questioning
Fluid balance chart
Treatment chart
Neurological New focal neurological deficit, confusion, delirium, or coma. Note review
Patient questioning
Haematological Requirement for any of the following within the last 24 hr:
packed erythrocytes, platelets, fresh-frozen plasma, or
cryoprecipitate.
Treatment chart
Fluid balance chart
Wound Wound dehiscence requiring surgical exploration or
drainage of pus from the operation wound with or without
isolation of organisms.
Note review
Pathology result
Pain New postoperative pain significant enough to require
parenteral opioids or regional analgesia.
Treatment chart
Patient questioning
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 56 1st December 2011
Mobility Unaided, aided, crutches, zimmer, wheelchair, bedbound Note review
Patient questioning
1: Pulmonary Yes No
Has the patient developed a new requirement for oxygen or respiratory support? � �
2: Infectious
Is patient currently on antibiotics and/or has the patient had a temperature of � 38° C the last 24 hours? � �
3, 4 & 5: Renal
Does the patient have any of the following?
Oliguria (<500ml/d) � �
Creatinine (>30% from pre-op level) � �
Urinary catheter in-situ � �
6 & 7: Gastrointestinal
Unable to tolerate enteral diet (oral or tube feed)? � �Is the patient experiencing nausea, vomiting or abdominal distention? � �
8, 9, 10 & 11: Cardiovascular
Has the patient undergone diagnostic tests or therapy within the last 24 hours for any of the following?
New MI � �
Ischaemia or hypotension (requiring drug therapy or fluid therapy
>200ml/h) � �
Atrial or ventricular arrhythmias � �
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 57 1st December 2011
Cardiogenic pulmonary oedema / new anticoagulation � �
12: Neurological
Does the patient have new confusion, delerium, focal deficit or coma? � �
13: Wound complications
Has the patient experienced wound dehiscence requiring surgical exploration or drainage of pus from the operative wound with or without isolation of organisms? � �
14 & 15: Haematological
Has the patient received transfusion of any of the following within the last 24 hours?
Red blood cells � �
Platelets / FFP/ Cryoprecipitate � �
16: Pain
Has the patient experienced surgical wound pain significant enough to require parenteral opioids or regional analgesia? � �
17: Mobility
Wheelchair/ Unaided / Aided / Crutches / Zimmer / Bedbound …….. �
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 58 1st December 2011
Appendix 5: EQ5D questionnaire (EuroQoL)
Is patient able to give answers to EQ5D? YES / NO
IF YES THEN ASK EQ5D QUESTIONS. IF NO THEN FOR EACH GROUP BELOW
PLEASE INDICATE WHICH STATEMENTS BEST DESCRIBE THE ABOVE NAMED
PERSONS HEALTH STATE TODAY. PLEASE RING ONE ANSWER IN EACH
QUESTION
We are trying to find out what you think about your health. I will ask you a few brief
and simple questions about your own health state today. I will explain the task fully
as I go along but please interrupt me if you do not understand something or if things
are not clear to you. Please also remember that there are no right or wrong answers.
We are interested here only in your personal view.
First I am going to read out some questions. Each question has a choice of three
answers. Please tell me which answer best describes your own health state today.
Do not choose more than one answer in each group of questions.
IF RESPONDENT HAS DIFFICULTY IN ANSWERING THEN REPEAT QUESTION
VERBATUM. FOR EACH QUESTION, RING APPROPRIATE NUMBER ON
ANSWER SHEET.
Question 1: Mobility
First I'd like to ask you about mobility.
Would you say you have…
1. No problems in walking about?
2. Some problems in walking about?
3. Are you confined to bed?
Question 2: Self-Care
Next I'd like to ask you about self-care.
Would you say you have…
1. No problems with self-care?
Downloaded From: on 08/29/2018
Optimise Protocol Version 4.0 59 1st December 2011
2. Some problems washing or dressing yourself?
3. Are you unable to wash or dress yourself?
Question 3. Usual activities
Next I'd like to ask you about usual activities, for example work, study, housework,
family or leisure activities.
Would you say you have…
1. No problems with performing your usual activities?
2. Some problems with performing your usual activities?
3. Are you unable to perform your usual activities?
Question 4: Pain/Discomfort
Next I'd like to ask you about pain or discomfort.
Would you say you have…
1. No pain or discomfort?
2. Moderate pain or discomfort?
3. Extreme pain or discomfort?
Question 5: Anxiety/Depression
Finally I'd like to ask you about anxiety or depression.
Would you say you are…
1. Not anxious or depressed?
2. Moderately anxious or depressed?
3. Extremely anxious or depressed?
PLEASE REMEMBER IT IS IMPORTANT TO HAVE ONE AND ONLY ONE
RESPONSE TO EACH GROUP OF THREE RESPONSES
Downloaded From: on 08/29/2018